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INTRODUCTION 
In the past few years, an increasing interest has been shown to prolactin and its possible 
action in the regulation of endocrine functions in mankind resulting in many good reviews 
dealing with these problems (Cowie and Tindal, 1971; Ho Yuen et al., 1973;НоттоЫп(а), 
1973; Pasteeis and Robyn, 1973; and Sulman (a), 1970). This development is mainly due to 
the fact that prolactin has been recognized as one separate entity in the human and that 
methods have been developed sensitive enough to measure its concentration in plasma. 
Before dealing with the problem of prolactin and ovarian function in the human female, 
however, it seems reasonable to give a short summary of the history of this hormone and its 
functions in different species for a better understanding of the different actions in the 
human. 
PROLACTIN IN VERTEBRATES 
The first real evidence that the anterior pituitary produced a mammotrophic hormone 
inducing copious milk secretion in the mammals was established by Strieker and Grueter in 
1928 (see Strieker, 1951). Shortly thereafter, Riddle and co-workers prepared partially 
purified pituitary extracts demonstrating the same lactogenic response with the 
concomitant property of stimulating the secretory activity of the pigeon crop sac. His group 
introduced the name Prolactin (Riddle et al., 1933). 
Until 1963, prolactin was solely regarded as a mammotrophic and gonadotrophic 
(luteotrophic) hormone. However, since the review of Riddle in 1963 in which he 
emphasized that it should be regarded as having metabolic properties next to reproductive 
properties, it has become clear that this hormone plays a significant role in various 
physiological processes (Riddle, 1963). In a review by Nicoli and Bern (1972), 84 different 
actions of prolactin were reported among cyclostomes, teleosts, amphibians, reptiles, birds 
and mammals. Unlike other adenohypophyseal hormones, prolactin did not show a specific 
action for the regulation of one single physiological process. Following Nicoli and Bern 
(1972), its actions can be classified as follows related to: 
1. Reproduction 
2. Osmoregulation 
3. Growth promotion 
4. Ectodermal structures 
5. Synergism with steroid hormones or action on organs which are also influenced by 
steroids. 
By using these headings, the described actions of prolactin in mammals regardless of the 
animal species are shown in Table 1 (L'Hermite, 1973). From this table it is clear that the 
influence of prolactin on many of these functions can only be secondary and that it has to 
interfere with other regulatory processes. No common denominator has been demonstrated 
for the actions of prolactin in the mammals (Nicoli and Bern, 1972). However, the 
possibility of prolactin to act without interfering with the second messenger (cyclic-AMP) 
makes it different from other pituitary hormones and could explain its permissive role on the 
responsiveness of different organs to other endocrine regulatory mechanisms (Horrobin (b), 
1973). 
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Table 1: Biological Actions of Prolactin, as Described in Mammals Regardless of Species 
Reproduction 
Mammary development 
Lactation 
Luteotrophic action 
Fertility control 
Luteolytic action 
Advanced puberty 
Decreased copulatory activity 
Parental behaviour 
Vaginal mucification 
Effect on male accessory sex glands 
Preputial gland size and activity 
Increased androgen binding in prostate 
Increased cholesterol in testis 
Increased glucuronidase activity in testis 
Osmoregulation 
Lactation 
Increased retention of sodium, potassium 
and water 
Ectodermal structures 
Mammary development 
Lactation 
Effects on sebaceous and preputial glands 
Hair maturation 
From: L'Hermite, M.: (1973) The present 
Endocrinology and Metabolism, W.B. S 
(Minor modifications made by editor) 
Growth promotion 
Mammary development 
Male accessory gland development 
Luteotrophic action 
Spermatogenesis 
Erythropoietic effect 
Hair growth 
Sebaceous and preputial gland growth 
Synergism with steroids 
Mammary growth 
Milk secretion 
Advanced puberty 
Luteotrophic action 
Spermatogenesis 
Renal retention of sodium, potassium and 
water 
Vaginal mucification 
Effects on male accessory sex glands 
Sebaceous and preputial glands 
Secretion 
Hair growth 
Actions like growth hormone 
Lipid deposition and/or mobilization 
Hyperglycemic-diabetogenic action 
Effects similar to HGH on sodium 
balance, NEFA and calcium meta-
bolism 
s of Prolactin Assays in Clinical practice. Clinics in 
ers Company, London, pp 426, with permission. 
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PROLACTIN IN MAN 
After the demonstration of prolactin in the anterior pituitary of different vertebrates, 
highly purified extracts of this hormone were isolated from different species (Riddle, 1963). 
Ovine prolactin was demonstrated as early as 1937 by White and co-workers, and its 
molecular structure has recently been described (Li, 1972). However, although there was a 
strong belief that prolactin also existed in the human, direct evidence could not be found. 
Indirectly, prolactin was demonstrated by the rather unspecific pigeon-crop-sac assay and 
later on by more specific in vitro bioassays using induction of different enzymes or amino 
acids in mammary tissue from different animals. The quantitative in vitro bioassay of 
Loewenstein with co-workers (1971), inducing N-acetyllactosamine synthetase by prolactin, 
was especially useful. This enzyme is necessary for the transformation of N-acetyl-
glucosamine and UDP-galactose to N-acetyllactosamine. The quantitative in vitro bioassay 
using the amount of produced 32p.caSeine, a prolactin dependent function, was also very 
useful (Turkington, 1971). 
Both Human Growth Hormone (HGH) and Human Placental Lactogen (HPL) exhibit 
lactogenic activity in all developed bioassays, and it was doubted by different investigators 
if prolactin really existed as a separate entity at all. All differences in growth promoting or 
lactogenic activities could be due to chemical degradation during purification of one single 
homogeneous protein with both activities intrinsic to it (Chadwick et al., 1961; Apostolakis, 
1968; Forsyth, 1969; and Lyons, 1969). 
At the same time during 1960 to 1970 an increasing amount of evidence was collected 
favouring the view of one prolactin next to HGH and HPL. The experiments of Pasteéis and 
co-workers were convincing in which they showed that prolactin producing cells in the human 
pituitary existed and also that when pituitary cells were cultured in vitro, HCG-activity 
decreased with an increase in the lactogenic activity (Pasteéis, 1963, 1969). Histologically, a 
difference between somatotrophic cells and prolactin cells was found using the tetrachrome 
staining technique of Herlant (1960) in human pituitaries. The prolactin cells were very 
scarce except during pregnancy and lactation (Herlant and Pasteéis, 1967). Lactation was 
also reported in dwarfs with isolated HGH deficiency (Rimoin et al., 1968), and low serum 
levels of HGH were found in conditions associated with galactorrhea (Benjamin et al., 
1969). Also, pituitary tumors were reported to be rich in a material causing prolactin-like 
activity in different bioassays without an increase in the amount of measurable HGH 
(Takatani et al., 1967; Peake et al., 1969). The inactivation of the lactogenic activity in 
human blood samples with an antiserum against ovine prolactin, but not with an 
antiserum against HGH, finally pointed out prolactin as a separate protein entity (Frantz et 
al., 1972(a)). 
Incubation studies with rat anterior pituitary glands and radioactive amino acids 
demonstrated a release of prolactin from the glands into the culture medium (MacLeod et 
al., 1969; Birge et al., 1970). When doing these studies with monkey and human pituitary 
glands, Friesen's group was the first one to demonstrate a similar protein in these two 
species next to GH. Also, the chemical amount was extremely small compared to HGH 
(Friesen et al., 1970). However, the biosynthesis of human prolactin had been 
demonstrated and very soon thereafter the hormone could be further isolated in larger 
amounts (Lewis et al., 1971 (a); Hwang et al., 1972). As expected, because of observed 
immunological cross reaction, human prolactin is very closely related to ovine prolactin 
consisting of one peptide chain of 198 amino acids with three disulfide bridges and a 
molecular weight of about 23,000. HGH and HPL (HCS) have both a single peptide chain 
of 191 amino acids with two disulfide bridges which are found at the same amino sequences 
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Comparison of the amino acid sequences of HCS (HPL), HGH, and Prolactin (Pr). 
The first fourty amino acids of the prolactin sequence are those of human prolactin. 
Homologous sections of the remaining amino acids are derived from the sequence of ovine 
prolactin. Homology is indicated as follows: Identical pairs by a vertical bar, highly 
acceptable pairs by three dots, and acceptable pairs by a single dot. Nonhomologous pairs 
are indicated by a cross. 
(From: Textbook of Endocrinology, Ed. Robert H. Williams, Page 47, Fifth Edition, 1974, 
W.B. Saunders Company, Philadelphia, U.S.A. With Permission) 
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as two of the three ones in human and ovine prolactin (Li, 1972; Niall, 1972; Lewis et al., 
1972). In Fig. 1 the primary structure of these hormones are compared to each other. 
Radioimmunoassays were available for rat prolactin (Kwa et al., 1969). Because of the 
noticed cross-reaction with ovine prolactin, heterologous assays for human prolactin were 
developed using antisera raised against ovine prolactin. After a short time, however, 
sufficient amounts of human prolactin were purified to raise antisera against it to develop 
highly sensitive homologous radioimmunoassays (Guyda et al., 1971; Hwang et al., 1971; 
Lewis et al., 1971 (b); Friesen et al., 1972 (a); and Sinha et al., 1973). All these assays gave 
comparable results in terms of physiopathological findings in man, but because of the large 
variations in the absolute values, it may be that the antibodies bind to different 
immunological sites of the prolactin molecule. As in all radioimmunoassays, there is a need 
for international standardization. At this moment, different groups are discussing these 
problems to find a suitable solution. 
During the last few years an extremely large amount of information has been published 
concerning the physiopathology of human prolactin because of the availability of the 
radioimmunoassays mentioned. Many of the postulated functions in the human being are 
still hypothetical and only those will be mentioned which definitely seem to be of some 
importance (Compare Table 1). 
Central Regulation 
Prolactin, like other protein hormones, is produced in the anterior pituitary gland under 
control of the hypothalamus. In contrast with the gonadotrophic hormones, prolactin 
release is controlled by a Prolactin Inhibiting Factor (PIF) produced within the 
hypothalamus. This factor has not as yet been isolated, but an increase of the dopamine 
concentration in the neurons of the hypothalamus decreases the release of prolactin from 
the pituitary. The presumption was that dopamine increased the amount of PIF within the 
hypothalamus. 
Dopamine itself is not able to cross the blood-brain barrier. L-dopa, however, does and 
is converted into dopamine within the hypothalamus. Administration of this drug indeed 
lowered peripheral plasma levels of prolactin in women with galactorrhea (Malarkey et al., 
1971). Recent studies have been undertaken in vitro, demonstrating a direct inhibitory 
effect of dopamine itself at the pituitary level which can be inhibited in a dose-dependent 
way using drugs interfering with its action. Therefore, at the present time, it seems 
reasonable to believe that dopamine itself is PIF which, once released within the 
hypothalamus, will be transported via the venous system to the pituitary where it exerts its 
action (Smalstig and Clemens, 1974; Takahara et al., 1974; Dibbet et al., 1974). In the case 
of hyperprolactinemia, L-dopa administration can help us to differentiate between an 
autonomous pituitary prolactin producing adenoma or a secondary hyperplasia of the 
prolactin producing cells due to hypothalamic disorder. 
Synthetic Thyrotrophin Releasing Hormone (TRH) has been found to release prolactin 
from cultured rat pituitaries (Tashjian et al., 1971). Soon thereafter, in vivo studies in man 
also showed the same response (Bowers et al., 1971). Many investigators believe that TRH 
must be the long postulated Prolactin Releasing Factor (PRF). In fact, administration of 
TRH and dopamine in vitro studies in rats has shown that the prolactin response to TRH 
can be modulated by concomitant administration of dopamine without changing the 
response of TSH to TRH (Takahara et al., 1974; Dibbet et al., 1974). In the case of 
hypothalamic-hypophyseal dysfunction, administration of TRH can be used to investigate 
pituitary function. 
13 
Oestrogens are known to stimulate prolactin secretion in animals (Meites, 1969). This 
effect in man seems less clear. L'Hermite and co-workers (1972) reported an increase of 
prolactin in postmenopausal women treated with high dosages of oestrogens with advanced 
breast cancer. Prolactin increase has also been reported in male patients during oestrogen 
treatment (Frantz et al., 1972 (b)). The increase of prolactin during pregnancy in humans 
parallels the increase of oestrogens. In the monkey there is no prolactin increase until just 
before parturition. Because in monkey pregnancy the oestrogen metabolism is different 
compared to humans, this could explain the difference in prolactin metabolism. Oestrogens 
seem to have an indirect function via the hypothalamus to stimulate prolactin production in 
the pituitary and a direct influence on the hypophysis to stimulate release (Horrobin, 1973 
(c)). 
A large scale of different psychotrophic drugs have been reported to stimulate prolactin 
release by acting indirectly on the hypothalamus (For reviews see: Sulman, 1970 (b); 
Verhoeven, 1974). The phenothiazines are of special interest because of the frequent use 
and the clinical importance of these drugs. Their action, as known so far, seems to be a 
depletion of catecholamines within different areas of the brain reducing the PI F content in 
the hypothalamus and, thus, inducing prolactin release. In the case of hypothalamic-
hypophyseal dysfunction, administration of chlorpromazine has become a useful test in 
examining responsiveness of this axis (L'Hermite, 1973). 
Insulin induced hypoglycemia induces prolactin release (Frantz and Kleinberg, 1970). A 
dose of 0.2 units of insulin per kg must be given to obtain a constant response (Frantz et al., 
1972 (b)). The administration of insulin has to give a quick drop in the blood glucose 
levels, otherwise the prolactin response is blunted. The action is thought to be via the 
hypothalamus and this response can be used to measure the hypothalamic-pituitary axis 
(Copinschietal., 1972). 
Ergot-alkaloids, especially 2-Bromo-a-ergocryptine (Bromergocryptine, CB 154, 
Sandoz, Basel, Switzerland) can inhibit prolactin secretion due to a direct action on the 
prolactin producing pituitary cells. The clinical importance of this drug seems to be great 
and in the different articles presented in this thesis more information will be given 
concerning this drug. 
Combining the effect in the different drugs mentioned so far (TRH, L-dopa, insulin, 
chlorpromazine and Bromergocryptine) and because of the availability to measure prolactin 
by radioimmunoassay, hypothalamic-hypophyseal (dys)function can be examined very 
carefully. It must be stated that because of the changing values of prolactin in plasma by a 
diurnal rhythm and by an intermittent release, isolated samples do not give accurate 
information. If possible, pharmacodynamic tests should be undertaken as described by 
L'Hermite (1973) before conclusions can be drawn whether this axis is intact or not. 
Normal blood levels 
Many studies have been reported dealing with normal values in males, females, and 
children. Among the different investigators, slight differences among the absolute values 
are found. This can be explained due to the use of different standards and especially to 
intrinsic differences related to the type of assay. The mean level in adult males is about 
5.0 ng/ml plasma (range: 0-28 ng/ml), in adult females 8.1 ng/ml plasma (range: 
0-28 ng/ml), and in children 10.8 ng/ml plasma (range: 7-17 ng/ml) (Horrobin (d), 1973). 
Friesen et al., (1972 b) reported no statistically significant difference between children and 
adults. The mean value for female compared to male is slightly higher. It is not yet 
established whether this sex linked difference is statistically significant or not. 
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24 hour secretion pattern 
Both in male and in female, prolactin demonstrates a circadian rhythm with maximum 
serum prolactin levels between 1 and 5 a.m. (Nokin et al., 1972) During the morning these 
levels decrease to a minimum between 10 a.m. and 12 noon. This rhythm is not necessarily 
related to the cycle of sleeping and waking and the physiological importance is not yet 
understood (Vanhaelst et al., 1973). 
Menstrual cycle 
The reports on changes in plasma prolactin levels during the human menstrual cycle 
have been conflicting. L'Hermite and co-workers reported a small prolactin peak at 
midcycle concomitant with the preovulatory oestrogen peak, and higher levels of prolactin 
during the luteal than the follicular phase of the cycle (L'Hermite et al., 1972; Robyn et al., 
1973). This increase fits well with the increase of oestrogens at the same time. Other groups 
have failed to demonstrate this (Hwang et al., 1971; Friesen et al., 1972 (a)), although 
higher levels were found in some women during the luteal phase (McNeilly and Chard, 
1974). It is my opinion that this should be examined more carefully by drawing frequent 
blood samples throughout the days around the ovulation or by estimating prolactin in urine 
during the cycle. Also we have to keep in mind that until now, all reports have dealth with 
plasma levels of this hormone. However, this gives no information about the tissue 
concentration of the hormone or the amount of hormone receptors at a given time which 
can depend on factors other than only the release of prolactin from the pituitary gland. 
In conditions with galactorrhea and menstrual disturbances, the role of increased 
plasma prolactin concentration on reproductive endocrinology is obvious. These conditions 
will be discussed more in detail in the second article of this thesis. 
Pregnancy 
From the onset of the human pregnancy there is a steady increase in plasma prolactin 
levels, reaching a maximum during the third trimester of about 200 ng/ml plasma (Tyson et 
al., 1972). As mentioned earlier, this increase does not take place in monkeys, and the 
difference between these two species could be due to the nearly complete lack of oestrogens 
in pregnant monkeys. 
Surprisingly, however, both human and monkey amniotic fluid were found to contain 
large amounts of immunoreactive prolactin indistinguishable from pituitary prolactin. 
The maximum concentration occurs around midpregnancy with a mean of approximately 
4000 ng/ml amniotic fluid with a slight decline thereafter until term. There is little transfer 
of the hormone from the amniotic fluid into the foetus, or from the mother into the 
amniotic fluid. According to present findings, the chorion seems capable of producing 
prolactin. The function of this high hormone concentration is unknown. However, 
osmoregulation seems a possible explanation (Friesen et al., 1973). 
The role of prolactin on lactation and the plasma levels of prolactin during the 
postpartum period will be discussed in the first, third and fourth article in this thesis. 
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Osmoregulation 
Administration of ovine prolactin to normal subjects has been shown to decrease renal 
excretion of sodium, potassium, and water with a slight increase in plasma sodium 
concentration and osmolarity (Horrobin, (e), 1973). Other groups have reported a slight 
increase of plasma prolactin levels in patients with advanced renal failure (Friesen et al., 
1972 (a); Frantz et al., 1972 (b)). In a recent report it was shown that in patients with 
hyperprolactinemia, a waterload did not decrease plasma prolactin levels as in normal 
controls. A delayed excretion of this waterload and lack of an adequate solute excretion in 
the hyperprolactinemic subjects were found to support the concept that prolactin plays a 
significant role in renal handling of water and solute (Buckman et al., 1974). We have to 
keep in mind, however, that in patients with elevated prolactin secretion, steroid 
production in the gonads seems to be decreased. Comparing these patients to normal 
controls, therefore, can not give exact information about prolactin and renal function 
(Thomer et al., 1974; Article two, three and four, this thesis). The vascular changes during 
pregnancy with the tendency of increased water and sodium retention could be due to the 
increasing amount of prolactin throughout pregnancy. Studies have to be undertaken to 
identify this mechanism. 
Prolactin and thyroid function 
The precise relationship between prolactin and thyroid function is not yet known. The 
previously reported finding that TRH releases both TSH and prolactin led to the question 
whether prolactin could play a role in the physiological control of the thyroid gland. This 
does not seem to be the case. It might, however, give an explanation for the clinical pictures 
of thyroid dysfunction, galactorrhea and menstrual disturbances. 
In hypothyroidism due to thyroid failure, an increase of TSH can be measured as a 
reaction to the lack of feedback mechanism of thyroxine on TRH release. In these cases 
elevated prolactin levels sometimes are found together with galactorrhea and oligo- or 
amenorrhea which completely cured after thyroxine replacement therapy (Kinch et al., 
1969; Edwards et al., 1971). That the prolactin did not completely correlate with TSH can 
be explained by keeping in mind that prolactin secretion next to TRH also is controlled by 
an inhibitory mechanism not affecting the TSH release. 
In humans, there also have been some reports dealing with the rare syndrome of 
prepubertal primary hypothyroidism, galactorrhea and precocious puberty (Van Wyck and 
Grumbach, 1969). In these children the combination of hypothyroidism and galactorrhea 
can be explained by lack of thyroxine to inhibit TRH secretion. Elevated prolactin levels 
have been measured and thyroxine replacement reduced these levels to normal with 
cessation of the galactorrhea (Horrobin (f), 1973). To give an explanation for the 
precocious puberty is rather difficult. As will be shown later, prolactin is thought to 
decrease the sensitivity of the ovaries to gonadotrophins in adults. Recently, it has been 
shown that gonadotrophins (FSH and LH) and TSH all consist of two peptide subunits, 
namely the α - and β -chain. The a -chain seems to be nearly similar in all three hormones, 
and between TSH and LH there is also an overlap of at least 50% in the β -chain. It is 
possible that in children the increased amount of TSH itself could have some luteotrophic 
effect, but the pituitary gland could also release incomplete TSH with increased 
luteotrophic effect due to the continuous hyperactivity because of the elevated TRH: This 
luteotrophic effect would then overcome the role of prolactin (Daughaday, 1974). 
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In the case of hyperthyroidism, the same picture could be expected if the disease was due 
to hypothalamic overproduction of TRH. Patients have indeed been reported with this 
disease combined with galactorrhea and hyperoestrogenic menstrual disturbances (Zondek 
et al., 1951). 
Prolactin and human breast cancer 
At least in the rat it has been established that prolactin and oestrogens are the principal 
hormones involved both in breast tumor growth and regression (Pearson et al., 1969; 
McGuire et al., 1974). In man, however, there exists a controversy about this mechanism. 
Both surgical hypophysectomy, which abolishes prolactin secretion, and pituitary stalk 
section, which mainly results in increased prolactin secretion, can produce regression of 
tumor growth in breast cancer patients (L'Hermite, 1973). 
Measurement of prolactin concentrations in patients with breast cancer and without did 
not give a significant difference in these concentrations (Wilson et al., 1973; Boyns et al., 
1973; Kwa et al., 1974). When plasma levels of prolactin from members of breast cancer 
families (high-risk group) were compared to the levels in breast cancer patients and 
controls, the prolactin levels in the high risk group were significantly higher than in the 
others (Kwa et al., 1974). This could indicate a role of prolactin in the development of the 
tumor rather than in maintenance of tumor growth once the tumor has developed. Also in 
rats which respond to 7,12-dimethylbenz (a) anthracene (D.M.B.A.) treatment with 
breast cancer development, there was a correlation between plasma prolactin levels and the 
genetically determined susceptibility to breast cancer (Wilson et al., 1973). 
At the present time radioreceptorassays for prolactin have been developed showing 
binding of prolactin to mammary cell membrane-suspensions (Shiu et al., 1973). McGuire 
and co-workers demonstrated prolactin receptors in rat breast cancer tissue (Costlow et al., 
1974). Culture studies using tissue from human breast carcinomas are at the moment being 
undertaken to establish whether these are prolactin-dependent or not (McGuire et al., 
1974). Using the new technique mentioned above, it is my personal opinion that the role of 
prolactin on both breast cancer development and growth will be more fully understood in 
the near future. 
Experimental models of this thesis 
The influence of prolactin on different endocrine functions in the human female can be 
studied in vivo comparing hormonal data of patients with hyperprolactinemia or lactating 
women to normal, nonlactating controls. Using the effect of Bromergocryptine, however, 
patients can be followed before and during administration of this drug. This allows us to 
observe clinical and hormonal changes within one and the same subject as the amount of 
prolactin decreases back to normal. Another possibility is to compare lactating and non-
lactating, Bromergocryptine treated women to each other during the early part of the 
Puerperium at which time prolactin levels are known to be elevated (Tyson et al., 1972). 
The first article of this thesis deals with the effect of Bromergocryptine on puerperal 
lactation. The three following papers give information on the influence of prolactin on 
ovarian function in the human female using the two experimental models as mentioned 
above. 
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Summary 
Inhibition of lactation by the new peptide ergot alkaloid 2-Br-a-ergocryptine 
(CBI54) was studied in a double-blind trial Forty patients divided into four groups 
were treated during seven consecutive days with daily doses ofeither 2 5 mg , 5 · 0 mg , 
7 5 mg of CBI54 or a placebo In terms of milk secretion, engorgement and pain 
the CBI54 therapy was signidcantly better than the placebo Tolerance of CB154 
was good and no drug-related side effects were observed In a further trial CB154 
was tried in five patients with already established lactation and in 22 patients who 
had not responded to standard hormonal therapy With one exception (suppression 
of lactation after four months of full breast-feeding) excellent results were 
achieved 
For prevention as well as for the suppression of already established lactation, the 
following dosage schedule ofCBl 54 is effective and avoids a rebound phenomenon: 
2 5 mg twice daily for two weeks, followed by 2 5 mg once daily for one week 
UNTIL recently, the inhibition of lactation has 
been attempted by one or more of the following 
methods, (a) hormonal inhibition by oestrogens 
alone, or in combination with androgens; 
(b) mechanical compression of the breasts; 
(c) restriction of fluid intake, supplemented by 
diuretic agents 
Treatment with oestrogens, m combination 
with mechanical compression of the breasts, has 
been most effective with a failure rate of 10 to 
20 per cent, the same number of patients develop 
late mammary congestion after 10 to 14 days 
(Daniel et al, 1967; Hodge, 1967) For certain 
groups of patients this method of inhibition 
enhances the risk of thromboembolic complica-
tions in the puerpenum (Daniel et al, 1967, 
Jeffcoate et al, 1968). The third method, used 
alone, is ineffective 
Recently a new peptide ergot alkaloid, 
2-Br-a-ergocryptine, has been developed, which 
reduces the serum-levels of prolactin (Besser 
et al, 1972; Del Pozo et al, 1973). CB154 
(Sandoz, Basle) is 2-Br-a-ergocryptine methane 
sulfonate, a crystalline powder of yellowish-
white colour. The molecular weight of the free 
base is 654-5, that of the salt 750 6. The struc-
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Structure of CB154. 
ture of this preparation is shown in Figure 1. 
CB154 probably acts at the level of the pituitary 
gland (Del Pozo et al., 1973; Pasteeis et al, 
1971). The suppressive effect on lactation has 
been successfully proved in several animal 
studies (Billeter and Fliickiger, 1971; Fliickiger 
and Wagner, 1968) and also in puerperal 
women (Varga et al., 1972). In the same way, 
CB154 is active in women with galactorrhea 
and disturbances of the menstrual cycle 
(Lutterbeck et al, 1971; Besser et al, 1972; 
Leutenegger et al, 1972; Varga et al, 1973) and 
in men with galactorrhea and impotence 
(Besser et al, 1972). We report here the effect 
of CB154 on puerperal lactation and define 
effective dosage schedules. 
PATIENTS AND METHODS 
In a double blind trial using capsules of 
identical appearance, daily doses of 2-5 mg., 
5-0 mg. and 7-5 mg. of CB154 were compared 
with a placebo. Forty women who had given 
proof of sufficient lactation in a previous 
Puerperium were studied, in four groups of 10, 
for 17 days. For the first seven days each patient 
received at random a package of 21 capsules, 
one to be taken three times a day before meals. 
The first capsule was always given within two to 
six hours following delivery, and no other 
specific treatment was given. A summary of the 
distribution of the daily medication to these 
four groups is shown in Table I. In addition 
oxytocics, hypnotics or iron preparations were 
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TABLE I 
Dosage schedule for the 7 days of treatment 
Time 
0800 hours 
1300 hours 
1900 hours 
Total dose of 
CB154per 
day 
Group 
A 
2-5 mg. 
2-5 mg. 
2-5 mg. 
7-5 mg. 
Group 
В 
2-5 mg. 
2-5 mg. 
Placebo 
5 0 mg. 
Group 
С 
2-5 mg. 
Placebo 
Placebo 
2-5 mg. 
Group 
D 
Placebo 
Placebo 
Placebo 
None 
given in some cases. The effectiveness of treat­
ment with CB154 was assessed three times daily 
by recording milk secretion, engorgement of the 
breasts and complaints of pain, according to the 
rating scale shown in Table II. On the 7th day 
postpartum, when leaving the hospital, both the 
patients and the responsible doctor had to 
decide whether or not they were satisfied with 
the treatment so far; for the following ten days 
the patients were asked to record symptoms of 
mammary activity and on the 17th day they 
returned a questionnaire on the results of 
treatment. 
The four groups were statistically identical in 
TABLE II 
Determination of mammary activity 
(rating scale) 
Score Milk production (by palpation) Congestion Pain 
No milk 
Some drops 
Slight outflow 
Stream of milk 
Absent 
Mild 
Moderate 
Severe 
Absent 
Mild 
Moderate 
Severe 
terms of age, body-weight, duration of pregnancy 
and parity. Patients on medication which might 
influence their hormonal state and patients with 
hypertension (diastolic pressure more than 
100 mm. Hg) were excluded. If the medication 
had to be discontinued within the first 72 hours 
after delivery, the patient in question was 
excluded and another patient with the same 
dosage schedule was admitted to the study. The 
code of the group was not known to the investi­
gators before the study had been concluded. 
Possible side-effects of the medication were 
checked by daily measurement of blood pressure, 
pulse frequency and diuresis. Before and after 
the treatment, a full blood count was done and 
hepatic and renal function tests were performed. 
Statistical analysis of breast engorgement, pain, 
and the overall impression of the success of 
treatment on the 7th day, was made by the 2 I 
technique (Kullback et al., 1962). Blood pressure 
and pulse frequency were analyzed by using the 
Wilcoxon test and the H test, the diuresis only 
by the H test. All other parameters could be 
assessed by analysis of variance. 
RESULTS 
There was a very clear difference in the success 
of treatment between the placebo group and 
each of the CB154 groups regarding the overall 
clinical impression (Ρ<0·001) as shown in 
Table III. However, there was no statistically 
significant difference between the three groups 
treated with CB154. 
Inhibition of milk secretion. This was excellent 
in all groups treated with CB154. There was a 
statistically significant difference between the 
TABLE III 
Overall clinical impression of the effect of treatment by physician and by patients 
Group 
CB154 2-5 mg. daily 
CB154 5 0mg. daily 
CB 154 7-5 mg. daily 
Placebo* 
Good effect 
assessment by 
physician 
8 
10 
10 
0 
Number of patients 
assessment by 
patient 
8 
10 
10 
1 
Poor ι 
assessment by 
physician 
2 
0 
0 
10 
orno effect 
assessment by 
patient 
2 
0 
0 
9 
* Treatment stopped after four days by eight of ten patients. 
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TABLE IV 
Inhibition of milk secretion 
(Mean scores, see Table II) 
Groups 
2 5mg.OrCB154daily 
5 Omg. of CB154 daily 
7-5 mg of CB154 daily 
Placebo 
Mean scores on treatment days 
1 
0 50 
0 13 
0 50 
0-33 
2 
0 53 
0 37 
0 73 
1 00 
3 
0 53 
0-57 
0-57 
0 66 
4 
0-50 
0-43 
0-53 
1-50·· 
+ 
++ 
+H 
. 
» 1 + -Ы 
5 
0-71 
0-27 
0-50 
·»· 
6 
0-48· 
0-23 
0-27 
*** 
7 
0-52· 
0 1 3 
0-27 
**· 
* N — 9; increase of dosage in one case. 
** N — 8; interruption of placebo Irealmenl in two cases. 
*** N - 2; treatment continued in two cases only. 
+ - P < 0 0 5 . 
+ + = P < 0 01. 
f + -t P < 0 0 0 1 . 
treated groups and the placebo group (Ρ<0·01 
for the 2-5 mg. and 5-0 mg. daily dosages and 
P<005 for the 7-5 mg. daily dosage). When the 
three treatment groups are combined, the 
results are highly significantly better than the 
placebo group (P<0 001); between the three 
CB154 schedules no statistical difference was 
found. 
For this analysis the results from the fourth 
day were used, because in the placebo group 
treatment had to be stopped by eight of the ten 
patients because of mammary activity developing 
within 90 hours of delivery (Table IV; Fig. 2). 
Prevention of mammary engorgement. This was 
effective in all CB154 treated groups. On the 
other hand mammary engorgement appeared to 
a statistically significant degree more frequently 
in the placebo group than in the others (P<0 001 
for the groups treated with 5 -0 mg. and 7-5 mg. 
daily and P<0 05 for the group treated with 
2-5 mg. daily). There was also a clear difference 
between the 2-5 mg. group compared to the two 
others (Ρ<0·01), but there was no difference 
between the 5 0 mg. and the 7-5 mg. treated 
groups (Table V). 
Complaints of pain. These were much more 
frequent in the placebo group, with a statistically 
highly significant difference from the other three 
groups (P<0001). On the other hand between 
the three CB154 treated groups no statistical 
difference was shown (Table VI). When noticed, 
TABLE V 
Complaints of mammary engorgement during the 
first seven treatment days 
Not 
Present present 
CB154 2-5 mg daily 4 6 
CB154 5 0mg. daily 0 10 
CB154 7-5mg daily 0 10 
Placebo* 9 1 
I 
-p.} 
* Treatment stopped after four days by eight of ten 
patients. 
+ - P-cO-05. 
+ + --- P < 0 0 1 . 
4 4 + - P < 0 0 0 l . 
TABLE VI 
Complaints of pain during the first seven treatment days 
Not 
Present present 
CB154 2-5mg. daily 
CB154 5 0mg. daily 
CB154 7-5 mg. daily 
Placebo* 
3 
1 
2 
9 
7 
9 
8 -f+ + 
1 J 
* Treatment stopped after four days by ei 
patients. 
^ - P < 0 0 5 . 
1 f - P < 0 0 1 . 
* - * - + = P < 0 0 0 1 . 
+ + + 
ght о 
+++ 
f ten 
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Score 
1.5 
1.0 
0.5 
/ 2.5 mg- Group 
5.0 mg - Group 
— 7.5 mg - Group 
Placebo - Group 
ι 
_L 
5 6 7 
Days of treatment 
Fio. 2 
Mammary secretion. 
the complaints were mild or sometimes moderate 
but of short duration in the treated groups as 
opposed to the placebo group where the 
complaints in nine of ten patients became severe 
within 90 hours of delivery. 
Follow-up. Seven days of CB154 therapy was 
not sufficient in all patients to prevent lactation; 
a rebound phenomenon was seen in 21 patients 
within 72 hours of leaving hospital. In a further 
two patients the daily dose of 2 · 5 mg. was not 
high enough and had to be increased to 5 0 mg. 
in one case on the 6th and in the other on the 
8th treatment day. After three weeks of CB154 
medication the therapeutic effect was satisfactory. 
Only seven patients had no complaints at all, 
three in the 2-5 mg. group, one in the 5-0 mg. 
group and three in the 7-5 group. Of the 21 
women with rebound symptoms two were lost 
to further follow-up and another five were 
treated with hormones by their general 
practitioner; three of these five women showed 
a very slow recovery from their symptoms with 
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much discomfort. The remaining 14 patients 
received a second course of treatment with 
CBI54, being given 2-5 mg. twice daily for the 
first week, followed by 2-5 mg. once daily for 
the next week. Approximately one hour after 
starting the treatment the breasts had to be 
emptied mechanically in 11 cases because of 
excessive discomfort, but after 24 hours of 
medication all 14 patients were nearly free from 
symptoms and no fuither rebound phenomena 
were seen when treatment was discontinued two 
weeks later. 
Placebo group. Two patients must be mentioned 
separately. One of them had clear evidence of 
engorgement and milk secretion on the fourth 
and fifth days, but there was a very quick decline 
of her symptoms and she was discharged from 
hospital with no sign of mammary activity. The 
second patient showed mild to moderate symp-
toms of initial lactation from the third day and, 
when leaving the hospital, she was given a 
course of treatment as mentioned above, with 
the same good result. The other eight had to be 
considered as failures of therapy, and treatment 
was stopped within 90 hours after delivery. 
With seven of these eight patients we tried a 
delayed suppression of lactation by CB154 with 
the following dosage-schedule: 2·5 mg. thrice 
daily for the remaining three or four days in 
hospital, followed by one week of 2 · 5 mg. twice 
daily and one week of 2 • 5 mg. daily. The breasts 
were always emptied mechanically approximately 
one hour after commencing treatment. Just as in 
the patients with a rebound phenomenon, the 
complaints disappeared almost completely with-
in 24 hours, with no further signs of mammary 
activity after ceasing the medication. 
No statistically significant influence of CB154 
was demonstrated on blood pressure, pulse 
frequency, urinary output or the specific gravity 
of urine. All the laboratory examinations were 
within normal limits before and after the study. 
No side effects occurred as a result of CB154 
medication; various mild complaints such as 
nausea and giddiness were noted just as fre-
quently in the placebo group as in the treatment 
groups. 
DISCUSSION 
In our opinion CB154 demonstrated a better 
lactation inhibiting effect than the combination 
of hormonal and mechanical treatment pre-
viously used in our clinic. In particular the 
almost complete relief of pain and engorgement 
spared both the patient and the nursing staff 
many complaints, and justified the longer 
duration of treatment. The following dosage 
schedule seems to be optimal: starting within 
24 hours of delivery for the first two weeks 
2-5 mg. twice daily, followed by 2·5 mg. once a 
day for the third week. No further treatment is 
necessary. It was interesting that in the placebo 
group signs of mammary activity did not really 
become apparent until 40 to 72 hours after 
delivery. 
After completing this study in June 1972, we 
treated 22 patients, for whom hormonal sup-
pression had failed, with CB154, using the 
dosage schedule mentioned above, with the same 
excellent results. As CB154 acts by suppressing 
the release of prolactin from the pituitary gland, 
this supports the thesis that the steroid hormones 
act by some other mechanism, probably in the 
mammary gland itself (Tyson et al., 1972). 
In the same period we also used CB154 to 
suppress lactation in five mothers who needed 
this for various reasons after establishment of 
full mammary activity. With the same dosage 
schedule we had very good results in four 
patients; in one of ihem, treatment was only 
started 20 days postpartum. The fifth patient 
was our only failure of therapy: she had been 
breast feeding for four months, but because of 
mammary infection lactation had to be reduced. 
Three months after delivery her menstrual 
cycle was re-established. We had no success with 
a dosage of 7-5 mg. of CB154 daily. This might 
suggest another mechanism of regulation of 
physiological lactation, independent of prolactin, 
after re-establishment of the menstrual cycle. 
In patients with persistent prolactin-dependent 
galactorrhea, mostly in combination with 
amenorrhea or non-ovulatory oligomenorrhea, 
a quick cessation of milk production is seen 
during CB154 medication with restoration of 
ovarian function (Lutterbeck et al., 1971; 
Besser et al., 1972; Varga et al., 1973). Prolactin 
might suppress release of FSH and LH or 
inhibit the response of the ovaries to these 
hormones. Normal levels of gonadotrophins or of 
oestrogens and progesterone could in their turn 
inhibit the further release of prolactin (Reyes 
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et al, 1972, Zarate et al, 1972) To clarify this 
mechanism a further s'udy is now being under­
taken, comparing puerperal women whose 
lactation has been suppressed by CB154 with 
puerperal lactating women, an earlier restoration 
of ovarian function is expected in women treated 
with CB154 
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SUCCESSFUL TREATMENT OF GALACTORRHOEA 
AND AMENORRHOEA AND SUBSEQUENT 
RESTORATION OF OVARIAN FUNCTION BY A NEW 
ERGOT ALKALOID 2-BROM-a-ERGOCRYPTINE 
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Department of Obstetrics and Gynaecology, 'De Wever' Hospital, Heerlen, and 
* Department of Obstetrics and Gynaecology, University Hospital, Nijmegen, The Netherlands 
(Accepted for publication 29 October 1973) 
SUMMARY 
Three patients with galactorrhoea and menstrual disturbances, due to hyper-
prolactinaemia and of more than 2 years duration, are described. Administration 
of2-Brom-a-ergocryptine effectively lowered the plasma prolactin concentrations in 
all three patients and restored the normal cyclic ovarian activity. One pregnancy 
was noticed during therapy. The role of prolactin on ovarian function is discussed. 
2-Brom-a-ergocryptine seems to be an effective drug in the long-term treatment 
of galactorrhoea associated with menstrual disturbances. 
Abnormal lactation in combination with menstrual disturbances has until recently been 
regarded as a rather uncommon syndrome (Canfield & Bates, 1965; Thompson & Kempcrs, 
1965; Rankin et al., 1969). Owing to a growing world-wide interest in the mechanism re-
gulating the hypothalamic-hypophyseal-ovarian axis, and because of the development of 
sensitive radioimmunoassays for FSH and LH as well as human prolactin (Midgley, 1966, 
1967; Hwang et ai, 1971), the syndrome of galactorrhoea and amenorrhoea has attracted 
increasing interest. In the last few years a number of papers have been published con-
cerning this matter (Besser & Edwards, 1972; Besser et al., 1972; Turkington, 1972; Zarate 
et al., 1973). We traditionally distinguish between the Chiari-Frommel syndrome consisting 
of galactorrhoea and amenorrhoea following a presumably normal parturition (Chiari et al., 
1958; Frommel, 1958). Galactorrhoea with amenorrhoea, usually occurring in nulliparous 
women, is classified as the syndrome of Argonz-del Castillo (Argonz & del Castillo, 1953). 
In association with pituitary enlargement we speak of the Forbes-Albright's syndrome 
(Forbes et al., 1954). The primary cause of the development of these syndromes is not yet 
known. Patients have been reported evolving through the various syndromes with the 
additional manifestation at a later stage of Cushing's disease due to chromophobe adenomas 
of the pituitary gland (Young et al., 1967; Mahesh et al., 1969). 
Correspondence: Dr R. Rolland, Department of Obstetrics and Gynaecology, 'De Wever' Hospital, 
Heerlen, The Netherlands. 
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In general, however, hypothalamic dysfunction seems to be an acceptable hypothesis. 
This could lead to enlargement of the pituitary gland as a reaction to the continuous 
stimulus to produce prolactin. It is well known that during pregnancy the pituitary in-
creases in volume with concomitantly an increased prolactin production (Käser et al., 1967; 
Reyes et al., 1972). The common denominator in these examples does indeed seem to be 
high plasma levels of prolactin. An influence of prolactin on ovarian function is probable, 
although the exact mechanism of action is uncertain. There are indications that this takes 
place at the hypothalamic level, but also an antigonadotrophic effect of prolactin per se 
on the ovaries has been postulated (Reyes et ai, 1972; Zarate et al., 1972). 
2-Brom-a-ergocryptine (bromergocryptine, code name CB 154, (Sandoz, Switzerland)) is a 
new semi-synthetic tripeptide ergot alkaloid. This drug shows specific antigalactic activity 
almost free of side eñeets. This effect has been demonstrated in several experimental animal 
studies and also in puerperal women and in patients with non-puerperal galactorrhoea 
(Fliickiger & Wagner, 1969; Billeter & Fliickiger, 1971; Lutterbeck et al., 1971; Besser 
et al., 1972; Varga et al., 1972, 1973). For example, our group defined a useful dosage-
schedule for inhibition of puerperal lactation and also showed that previously established 
lactation, due in most cases to failure of hormonal therapy, could be supressed by this drug 
(Rolland & Schellekens, 1973). The pharmacological action of bromergocryptine is at the 
level of the pituitary gland and functions by blocking the release of prolactin from the 
hormone producing cells (Pasteeis et al, 1971 ; Del Pozo et al., 1973). By administration of 
this drug, the effect on galactorrhoea and the reaction of the hypothalamic hypophyseal-
ovarian axis to declining levels of prolactin, have been studied. 
SUBJECTS AND METHODS 
Three patients with galactorrhoea and menstrual disturbances treated with bromergo-
cryptine have been carefully studied. The degree of galactorrhoea is classified by an arbitrary 
scale of + + + / + + / + ranging from spontaneous profuse milk secretion from both 
breasts to only a few drops obtained by copious palpation. Urinary oestrogens and preg-
nanediol determinations were performed by standard methods (Eechaute & Demeester, 
1965; Brombacher et al., 1968a, b). Total urinary excretion of gonadotrophins was measured 
by the mouse uterus test as described by van Gilsc (1953). During treatment heparinized 
venous blood samples were frequently collected, centrifuged, and the plasma kept at — 20oC 
until assay. Prolactin was measured by an homologous radioimmunoassay kindly supplied 
by Dr H. Friesen, Montreal (Hwang et al., 1971). The values are expressed as ng/ml plasma. 
For the LH assay an anti-HCG serum, kindly provided by Organon, The Netherlands, was 
selected which showed minimal cross-reaction with FSH. As tracer, highly purified LH was 
used, prepared according to Closset et al. (1972). The FSH determinations were performed 
by an assay using antiserum Batch 3 adsorbed with HCG provided by the N.P.A. (U.S.A.) 
Both FSH and LH are expressed in mlU of the 2nd IRP of HMG, generously supplied by 
the Division of Biological Standards of M.R.C., Holly Hill, England. 
Case I (H.Ha) 
This patient had been under our care because of persistent galactorrhoea and amenorrhoea 
since the delivery of her first child in June 1970. An attempt to inhibit post-partum 
lactation with oestrogen-testosterone was unsuccessful. During the following 2 years she 
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also developed persistent frontal headache. Her previous history revealed a normal 
menarche at 15 years followed by a regular menstrual cycle until 1967 when oligomenorrhoea 
and later on amenorrhoea without galactorrhoea occurred. Ovulation was induced by 
injections of human menopausal gonadotrophin and human chorionic gonadotrophin 
(Organon, The Netherlands) which resulted in the previously mentioned pregnancy. 
The physical examination before bromergocryptine treatment showed an obese woman; 
body weight 78-8 kg, height 168 cm. A constant blood pressure of 150/110 mmHg was 
measured. The breasts were well developed with heavy milk flow induced merely by gentle 
palpation. This milk flow also occurred spontaneously during the night. The external 
genitalia together with the vaginal epithelium were moderately atrophic, showing no signs 
of oestrogenic activity. The uterus was small, the ovaries could not be palpated. A planigram 
of the sella turcica and visual field examinations were all reported as normal. The pre-
treatment laboratory findings are shown in Table 1. Hypo-gonadotrophic, hypo-oestrogenic 
TABLE 1. Initial laboratory studies in three patients with galactorrhoea and menstrual disturbances 
Case I Case II Case III Normal range in laboratory 
Total urinary 
gonadotrophins (MU) 
(mouse uterus) 
Urinary total 
oestrogens/24 hr (//mol) 
7-15 
005 
Urinary pregnanediol/24 hr (//mol) 0-2 
Urinary 17-ketosteroids/24 hr 37-43 
(//mol) 
Urinary 17-hydroxysteroids per 24 20-45 
hr (μηηοΐ) 
Fasting Cortisol plasma level 0-40 
Oenol/l) 
Thyroid function (TBG, T4) Normal 
HGH response to insulin — 
Oral glucose tolerance test Normal 
Normal cyclic women : 
5 40 50 10-70 MU 
Non-pregnant women: 
005 005-0· 12 004-0-40 /imol/24 hr ; 
1 //mol = 288 //g (oestriol) 
0-6 1 ·6-2·9 Non-pregnant women in luteal 
phase: 9-31 //mol/24 hr 
1 /«nol = 320 //g 
39-70 24-34 Normal cyclic women: 25-100 
/лтюІ/24 hr; 1 //mol dehydroepi-
androsterone = 288 //g. 
48-52 23-55 Normal women: 15-55//mol/24 hr; 
1 //mol dehydroepiandrosterone = 
288//g 
0-41 0-69 Normal women : 0-40-0.70 //mol/1 ; 
1 //mol = 362 //g 
Normal Normal 
— Normal 
Normal Normal 
amenorrhoea existed, combined with post-partum galactorrhoea. All other values determined 
at this time, fell within normal limits. After collection of some pre-treatment venous blood 
samples for later determination of prolactin, LH and FSH, treatment was started with 
2-5 mg bromergocryptine twice daily during meals. The clinical findings are summarized in 
Fig. 1. Within 4 weeks of therapy her galactorrhoea had disappeared completely and 
examination of the uterine cervix revealed very rich mucus showing full signs of oestrogenic 
activity. Her body temperature curve (BTC) shifted at this time and exactly 2 weeks later she 
E 
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menstruated for the first time in 3 years. An endometrial biopsy taken on the first day of 
vaginal bleeding showed a normal menstruating post-ovulatory picture. During the next 13 
weeks she had a regular menstrual cycle of 26-28 days with a biphasic basal temperature 
curve. Galactorrhoea did not recur after lowering the bromergocryptine dose to once 
daily 2-5 mg. Twenty weeks after starting therapy, amenorrhoea was noticed and a preg­
nancy test (Organon, The Netherlands) showed HCG activity as in pregnant women. 
Bromergocryptine medication was immediately stopped. At the moment she is in the last 
trimester of pregnancy, and routine controls have been so far uneventful. 
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F I G . 1. Case I: clinical findings during bromergocryptine therapy. 
The laboratory findings are summarized in Fig. 2. The immediate decrease in the pro­
lactin levels to normal prepregnant values below 30 ng/ml plasma is striking and demon­
strates clearly the strong effect of bromergocryptine. The pre-treatment FSH levels are in 
the high normal cyclic range as we in our laboratory find pre-ovulatory levels of approxi­
mately 8 m IU 2nd IRP/ml in normal cyclic women. The LH levels are in the normal cyclic 
range as established in our laboratory. This is in disagreement with the earlier determined 
low concentrations of total gonadotrophins in the 24 h urine measured by the mouse uterus 
test. The amount of oestrogens and pregnanediol are clearly below the levels found in the 
24 hr urine of normal cyclic women. As a reaction to the decrease of the plasma prolactin 
levels, an increase in the amount of excreted total oestrogens is noticable with thereafter an 
ovulatory LH as well as FSH peak. During the following weeks all levels of measured 
hormones are in the normal cyclic range with the expected fluctuations. At the end of the 
treatment period a high level of LH is found; as the patient was pregnant at this moment 
this must be due to cross-reaction with HCG. It is noteworthy that the FSH levels are 
undetectable at this time. 
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Case II {V.Lu) 
This 22-year-old nulliparous woman had been seen elsewhere because of spontaneous 
galactorrhoea noticed for the first time in May 1970. At the same time her previous re­
gulatory menstrual cycle became oligomenorrhoeic. Amenorrhoea appeared in January 
1972. Induction of ovulation by clomiphene had failed. During the last 2 years she also 
noticed moderately frontal headache. She married in June 1971, and a pregnancy was wanted. 
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FIG. 2. Case I: laboratory findings during bromergocryptine therapy. 
Her previous history revealed a late menarche at 17 years followed by a regular cycle. 
Physical examination before bromergocryptine treatment showed a healthy young woman 
with a body length of 161 cm and a body weight of 62 kg. Her hair distribution was female. 
The breasts were well developed and milk could easily be produced by gentle palpation. This 
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milkflow also occurred spontaneously, usually during the night. The external genitalia were 
normal, the vaginal epithelium was atrophic and no signs of oestrogenic activity could be 
demonstrated in either the vaginal epithelium or in the cloudy mucus of the cervix. The 
uterus was small, the ovaries could just be palpated. X-rays of the sella turcica and visual 
field examinations were all reported as normal. The pre-treatment laboratory findings are 
shown in Table 1. This patient also demonstrates a hypo-gonadotrophic, hypo-oestrogenic 
amenorrhoea combined with spontaneous but non-puerperal galactorrhoea. Treatment was 
started with 2-5 mg bromergocryptine twice daily during meals. The clinical findings are 
summarized in Fig. 3. Her galactorrhoea disappeared completely after 4 weeks of therapy. 
Examination of the cervix uteri at this time showed the typical aspects of good oestrogenic 
activity and 1 week later her BTC shifted to a hyperthermic plateau followed by a normal 
menstruation 12 days later. An endometrial biopsy taken on the first day of vaginal bleeding 
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FIG. 3. Case II: clinical findings during bromergocryptine therapy. 
showed an endometrial pattern as in the normal menstrual phase. During the next 10 
weeks she had a regulatory cycle of 30 days/4 days with a biphasic basal temperature curve. 
At the moment she is still on therapy without complaints. A pregnancy, however, has not 
occurred as yet. 
The laboratory findings are summarized in Fig. 4. Also here the strong inhibitory effect of 
bromergocryptine is demonstrated by the rapid decrease of the plasma prolactin levels. The 
FSH pre-treatment concentrations are in the low cyclic range; the LH levels, however, in 
the normal cyclic range. These findings are also in slight disagreement with the values of total 
urinary gonadotrophins previously found by bioassay. During therapy, the 24 hr urinary 
oestrogen excretion increases to normal values within 4 weeks followed by an increase in 
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the pregnanediol excretion to values similar to those seen in the normal luteal phase 1 
week later. At this time the BTC showed a hyperthermic plateau. Thereafter all hormone 
values are in the cyclic range with normal fluctuations. 
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CaseHIiG.A.) 
This 27-year-old patient had been under our care since November 1971 because of 
persistent galactorrhoea and oligomenorrhoea after the birth of her second child in June 
1970. In November 1971 amenorrhoea occurred. A microcurettage taken on the first day of 
her last vaginal bleeding showed endometrium with no signs of secretory activity. During 
this previous period breakthrough uterine bleeding could sometimes be provoked by 
progestagen administration. Her menarche was at 13 years followed by a regular menstrual 
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cycle of 32 days/3 days Just before starting bromergocryptine medication, a spontaneous 
menstruation was noticed with an endometrial biopsy showing poor secretory activity. 
Physical examination revealed a healthy women with female hair distribution. The 
breasts were well developed with much fibro-glandular tissue. Milk could be easily squeezed 
out of both breasts by gentle palpation. Her external and internal genital organs were 
normal with some signs of oestrogenic activity in the vaginal epithelium. Visual field-
examinations were normal Because of a doubtful double contour of the bottom of the sella 
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FIG 5. Case III clinical and laboratory findings during bromergocryptine therapy 
turcica seen on X-ray, tomography, carotid angiography and cerebral scanning were per­
formed, all with normal results The pre-treatment laboratory findings are shown m Table I. 
There existed a normogonadotrophic oligomenorrhoea with mostly low baseline urinary 
oestrogens in combination with moderate galactorrhoea. Other values were within normal 
limits. 
The clinical and laboratory findings during bromergocryptine treatment are summarized 
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in Fig. 5. Her galactorrhoea virtually disappeared within 4 weeks, thereafter only a few 
drops of milk could be expressed by heavy palpation of her left breast. Exactly 4 weeks 
after initiation of treatment, menstrual bleeding occurred showing endometrium in the 
late secretory stage with pseudodecidual reaction. Thereafter her menstrual cycle was quite 
regular with a period of 32 days/5 days. The moderate increased pre-treatment prolactin 
levels were immediately suppressed to normal values within 1 week of therapy and remained 
so during treatment. The pre-treatment FHS and LH levels were in the normal cycle range 
as was the excretion of urinary oestrogens and pregnanediol. As mentioned earlier, 
the patient had a spontaneous menstruation at this time, her first for 10 months. During 
treatment the gonadotroph ic hormones and also the steroids are in the normal cyclic range 
except for the excretion of oestrogens during the first treatment week. Lowering the dose of 
bromergocryptine to once daily 2-5 mg did not influence her menstrual cycle, and no increase 
in milk production was noticed. One month after stopping the medication her menstruation 
occurred on time. However, a slight increase of milk flow by palpation was noticed, mainly 
from her left breast. 
SIDE EFFECTS 
Serious side effects were not observed in any of the three patients apart from some episodes 
of nausea, gastric upset and drowsiness during initiation of therapy. Within 7 days of 
treatment no further complaints were reported when administrating the medication during 
meals. 
C O M M E N T 
In these three cases the essential role of prolactin in maintenance of non-puerperal galactor-
rhoea is demonstrated. The effectiveness of bromergocryptine in lowering plasma 
levels of prolactin is obvious. The immediate restoration of ovarian function to normal in 
the first two patients and probably also in the third one after return of prolactin levels to 
normal, strongly indicates an effect of prolactin on ovarian function. It has been postulated 
that the fall in prolactin levels has a stimulatory effect on the gonadotrophin-releasing 
factors in the hypothalamus which results in an increased secretion of gonadotrophins 
(Malarkey et al., 1971 ; Besser et al., 1972; Varga et al., 1973; Zarate et al., 1973). However, 
a number of cases with amenorrhoea and galactorrhoea have been reported with 
gonadotrophins in the normal cyclic range (Canfield & Bates, 1965; Rankin et al., 1969). 
Zarate et al. (1972) tried to stimulate the ovaries in the direct post-partum period in lactating 
women by administration of gonadotrophins, but no response could be demonstrated. Based 
on this evidence, Zarate et al. (1972) and other investigators believe in an antigonadotrophic 
action of prolactin at the level of the ovaries (Reyes et al., 1972). This fits in well with our 
observations in these three cases that normal plasma levels of gonadotrophic hormones are 
present concomitant with low normal to pathologically low levels of oestrogens. We now 
have evidence from a study in progress that this status also exists in normal lactating 
puerperal women. Recently it has been shown that prolactin has an affinity for ovarian 
tissue (Turkington et al., 1973). 
In cases of galactorrhoea and amenorrhoea due to pituitary enlargement with opthal-
mological or neurological complications, surgical intervention still seems the therapy of 
choice. If that is not necessary, progestational steroids in combination with oestrogens may 
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give temporary relief. Clomiphene therapy or administration of gonadotrophic hormones 
have shown various results in promoting fertility in these patient (Thompson & Kempers, 
1965; Rankin et al., 1969). In cases of gonadotrophin therapy, overstimulation of the ovaries 
is an additional disadvantage. Bromergocryptine indirectly restores ovarian function 
without overstimulation and thus promotes fertility in a physiological way. Teratological 
studies in rats and rabbits give no evidence of specific embryotoxic or teratogenic drug 
effect due to bromergocryptine (personal communication, Professor Dr E. Flückiger, 
Sandoz Ltd, Basle, Switzerland). Varga et al. (1973) reported one pregnancy while on 
bromergocryptine treatment with a healthy child as the outcome. Jaszmann & Sternthal 
(1973) reported three pregnancies during bromergocryptine medication. One had an early 
abortion and two others delivered healthy children after normal pregnancies (personal 
communication, Dr L. Jaszmann). If pregnancy is desired while on bromergocryptine 
medication, careful supervision is necessary with immediate cessation of medication as soon 
as a pregnancy is suspected, as shown in our first case. Otherwise mechanical contraceptive 
precautions should be recommended during drug therapy until more data have been 
collected concerning the teratogenicity of this drug. 
In the American literature there is a considerable amount of information concerning 
therapy with 1-dopa. This drug also effectively lowers the prolactin plasma levels and restora-
tion of ovarian function has been reported during long-term treatment (Malarkey et al., 1971 ; 
Turkington, 1972; Zarate et al., 1973). However, this drug seems inferior to bromergocryp-
tine because increasing amounts of the drug seem necessary to obtain a constant result 
(Besser & Edwards, 1972). In our opinion bromergocryptine is the drug of choice 
for treatment of the syndromes of galactorrhoea and amenorrhoea as well as for puerperal 
inhibition of lactation. It is still not yet clear whether long-term therapy with bromergo-
cryptine will completely cure these patients without a rebound phenomenon after cessation 
of medication. 
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SUMMARY 
Serial plasma levels of prolactin follicle-stimulating hormone (FSH), luteinizing 
hormone (LH), 17/i-oestradiol (E) and progesterone (P) were determined by radio­
immunoassay in ten healthy women during late pregnancy and puer perium 
until the occurrence of the first menstruation, at which moment an endometrial 
biopsy was taken. Prolacin concentrations, which were high during late preg­
nancy and the early post-partum period, declined thereafter but remained above 
30 ng/ml plasma during the period of breast feeding. FSH was nearly undetectable 
during late pregnancy and the first week post-partum but returned to normal 
levels between days 7 and 18. Thereafter relatively high FSH levels were found 
during the period of hyperprolactinaemia. Following clearance of human chorionic 
gonadotrophin (HCG) during the first 2 weeks post-partum, LH remained below 
the normal cyclic range in all cases for at least 28 days. Placental E and Ρ were 
fully cleared within 7 days. In spite of relatively high levels of FSH, E remained 
low as did LH during the period of hyperprolactinaemia. Thereafter E increased 
followed by an increase of LH, suggesting a positive feedback of E on LH release. 
The first menses observed in five subjects during the study were preceded by (subí-
normal Ρ levels for a relatively short period although the endometrial biopsies 
showed only late proliferative changes. 
In spite of an increasing number of publications concerning the mechanism controlling the 
re-establishment of normal cyclic hypothalamic-pituitary-ovarian function following 
delivery, this mechanism is still not yet fully understood. The duration of post-partum 
amenorrhoea is extremely variable, but tends to be related to the duration of full breast-
Correspondence: Dr R. Rolland, The Milton S. Hershey Medical Center, Department of Endocrinology, 
The Pennsylvania Stale University, Hershey, Pennsylvania 17033, U.S.A. 
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feeding (El-Minavi & Sadek Foda, 1971 ; Kamal et al., 1969; Berman et al., 1972). During 
lactation the first vaginal bleeding is usually anovulatory and ovulation has not been 
reported before 39 days after delivery. In women whose lactation has been suppressed 
immediately after delivery, ovulation has been demonstrated as early as day 36 (Perez et al., 
1972). 
Ovarian refractoriness to gonadotrophins has been suspected during the early post-
partum period as vaginal smears indicated low oestrogen production in spite of normal 
urinary excretion of gonadotrophins (Keettel & Bradbury, 1961), and exogenously admini-
stered gonadotrophins did not give a rise in urinary excretion of oestrogens in the immediate 
post-partum period in lactating women (Zarate et al., 1972). This could be due to an 
antigonadotrophic action of prolactin at the level of the ovaries as proposed by Reyes 
et al. (1972). However, Varga et al. (1973) believe in an antigonadotrophic action of pro-
lactin via the hypothalamus. 
The aim of the present investigation was to study the interrelationship between plasma 
levels of prolactin, follicle stimulating hormone, luteinizing hormone, 17/?-ocstradiol and 
progesterone in order to decide which component of the hypothalamic-hypophyseal-
ovarian axis is responsible for the delayed ovulation post-partum. Human placental lactogen 
(HPL) was also estimated. 
SUBJECTS 
Ten healthy volunteers, who had given proof of adequate lactation for more than 2 weeks 
in a previous Puerperium, were studied. Their menstrual cycles prior to pregnancy were 
reported as normal with a duration of approximately 4 weeks. The pregnancies, up to the 
beginning of the study in the 36th week, were all uneventful. 
Subjects were admitted to hospital when signs of labour were obvious. From the 36th 
week of pregnancy venous blood samples were drawn weekly, followed by daily collection 
during the first 7 days post-partum. Thereafter the samples were drawn twice weekly 
until the occurrence of the first vaginal bleeding recognized by the subject as a normal 
menstruation. Each subject then underwent an endometrial biopsy to determine the stage 
of endometrial development. If no vaginal bleeding had occurred within 90 days post-
partum, an endometrium biopsy was performed and the study was closed. 
The time interval between suckling and the drawing of the blood sample was noted, as 
were the number of breast feeds given each day. During the first 7 days post-partum nearly 
all blood samples were taken between 07.00 and 08.00 hours, thereafter always between 
09.00 and 12.00 hours. The blood was collected in heparinized tubes, immediately chilled on 
ice, centrifuged at 2500 rev/min for 8 min and the plasma was stored at —20oC until assayed. 
All samples from an individual subject were measured in the same assay run. 
H O R M O N E E S T I M A T I O N S 
Protein hormones 
Prolactin was measured by a homologous radioimmunoassay system provided by Dr 
Henry Friesen, (Manitoba). The general outline of the procedure followed is described by 
Hwang et al. (1971). Minor modifications have been made by ourselves. 
FSH. For measurement of FSH, the antiserum provided by the U.S. National Pituitary 
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Agency was used (Batch No. 3). For labelling with 125I, a highly purified human FSH was 
used (Code CPDS/2; gift from Dr W. Butt, Birmingham; biological activity 5400 lU/mg). 
LH. The determinations of human LH were performed with an antiserum directed against 
intact HCG. The highly purified human LH preparation (code HLH/LN) used for iodina-
tion was prepared according to Closset et. al (1972). The antiserum used was carefully 
selected for its specificity. Highly purified FSH (CPDS/2) and less purified preparations 
like LER 907 and the 2nd IRP of human menopausal gonadotrophin (HMG) showed a 
reactivity with this antiserum which suggested that it was only the contaminating LH which 
was active. 
HPL. The antiserum and highly purified HPL were obtained from Sciavo, Siena, Italy. 
The assay system was set up in such a way that undiluted sera could be measured directly. 
The antiserum is specific in that up to 140 /iU human growth hormone 1st IRP and human 
prolactin up to 300 ng/ml do not interfere in this assay. 
The 125I-labelled LH and FSH were purified prior to each assay by means of a small 
cellulose column (Lequin et al., 1974). Separation of antibody-bound and free hormone 
was performed in all instances by means of the double-antibody solid phase (DASP) 
technique developed by Organon, Oss, the Netherlands (den Hollander et al., 1972). 
Calculations were done by a computer program kindly made available to us by Dr David 
Rodbard, National Institutes of Health, Bethesda, Md. The coefficient of variation of each 
sample was in all instances less than 20% and was generally between 10 and 15%. 
The normal levels during a menstrual cycle of FSH and LH are shown in Table 1. In 
normal non-pregnant women prolactin is nearly always found below 30 ng/ml. HPL in 
those cases is below the limit of detection (<250 ng/ml). 
TABLE 1. Normal values of FSH, LH, 17/í-oestradiol and progesterone in 
plasma during the menstrual cycle 
Hormone 
FSH (mIU/ml) (2nd IRP) 
LH (mIU/ml) (2nd IRP) 
17^-Oestradiol (pg/ml) 
Progesterone (//g/dl) 
Stage of menstrual cycle 
Early to 
mid-proliferative 
2-10 
10-40 
50-100 
<0·12 
(Pre)ovulatory 
surge 
8-20 
140-500 
200-350 
Mid- to 
late luteal 
2-5 
10-60 
80-150 
>0·50 
Steroid hormones 
17)?-Oestradiol was measured by radioimmunoassay, using an antibody against 17/?-
Oestradiol-6-(0-carboxymethyl)-oxime. The antibody was a gift from Dr Exley, London, 
who has described its specificity in detail (Exley et al., 1971). The assay procedure was 
described by de Jong et al. (1973). The Sephadex LH-20 chromatography step was omitted 
in these estimations. Replicate assays of distilled water, to which [3H]17/?-oestradiol was 
added, yielded a result of 6-8+ 7-8 (s.d.) pg (n = 72) after correction for the mass of radio-
active steroid added. The precision of the method is characterized by coefficients of variation 
of 10-20% for samples containing 30-150 pg 17/?-oestradiol. 
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Progesterone. The concentrations of progesterone were estimated using radioimmuno-
assay. The method was described in detail by de Jong et al. (1974). Normal values for the 
concentration of 17/î-oestradiol and progesterone found during the cycle are shown in 
Table 1. 
RESULTS 
The duration of lactation and post-partum amenorrhoea and the stage of endometria 
development in the subjects studied are shown in Table 2. The mean duration of lactation 
was 46 days with a range of 9 to more than 96 days ; the mean duration of amenorrhoea was 
67 days with a range of 40 to more than 96 days. The endometrial biopsies showed signs of 
more or less marked proliferation in eight cases, although obvious secretory activity could 
TABLE 2. The duration of lactation and post-partum amenorrhoea ¡η ten 
women and the stage of endometrial development at the moment of the 
first vaginal bleeding after delivery 
Patient 
I 
II 
in 
IV 
V 
VI 
VII 
Ш 
IX 
X 
Mean 
Duration 
of lactation 
(days) 
30 
20 
9 
46 
> 96/96 
35 
> 93/93 
26 
> 42/42 
60 
46 
Duration of 
post-partum amenorrhoea 
(days) 
52 
57 
42 
87 
>96*/96 
65 
>93*/93 
60 
40 
>94*/94 
67 
Endometrium 
development 
Mid-proliferative 
Lale-proliferative 
Late-proliferative 
Late-secretory 
Early-proliferative 
Late-proliferative 
Early-proliferative 
Late-proliferative 
Late-proliferative 
Mid-secretory 
Range 9->96 40->96 
* Still amenorrhoeic. 
only be demonstrated in two cases. The time interval between duration of lactation and 
duration of amenorrhoea was more than 34 days in both cases (patients IV and X). 
Table 3 summarizes the most noteworthy changes in the hormonal status of these ten 
women. 
Two subjects (V and VII) were amenorrhoeic for more than 90 days; during this period 
they still breast-fed their children. Their hormonal status during this period was quite 
similar and the data of subject V are shown in Fig. 1. 
Subjects IV and X showed clear signs of secretory activity in their endometrial biopsies. 
According to the rise in plasma levels of progesterone above 0-50 /ig/dl, plasma ovulation 
must have taken place at about day 74 in subject IV and at day 78 in subject X. Their 
hormonal data were quite similar during the observation time and Fig. 2 shows the data of 
46 
TABLE 3. A summary of the most noteworthy changes in the hormonal status of ten women during physiological lactation 
»atient 
I 
II 
III 
IV 
V 
VI 
VII 
Щ 
DC 
X 
Duration 
of lactation 
(days) 
30 
20 
9 
46 
>96 
35 
>93 
26 
42 
60 
Prolactin 
> 30 ng/ml 
until day: 
41 
20 
15 
49 
96 
35 
93 
31 
Not clear 
53 
Ended HCG 
excretion at day: 
(approx.) 
10 
13 
9 
11 
15 
11 
8 
6 
11 
11 
FSH>2mIU/inJ 
at day: 
(approx.) 
15 
17 
12 
18 
18 
18 
7 
7 
14 
18 
FSH > eye. 
range 
(days) 
2(M4 
20-38 
15-29 
32-74 
29-85 
25-57 
15-93 
13-60 
\4-41 
37-81 
LH «eye. 
range 
(days) 
12-30 
13-31 
12-22 
15-60 
15-60 
14-66 
8-89 
7-28 
11-28 
U-74 
Oestradiol 
increase 
(day) 
30 
24 
19 
58 
Not clear 
39 
None 
40 
21 
67 
Progesterone 
increase 
(day) 
44 
48 
36 
78 
None 
57 
None 
49 
None 
78 
Day of 
vaginal 
bleeding 
52 
57 
42 
87 
>96 
65 
>93 
60 
40 
>94 
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FIG. 1. Subject V. The relationship between breast-feeding, peripheral plasma levels of pro­
lactin, FSH, LH, 17/?-oestradiol and progesterone during the Puerperium. (Horizontal lines 
indicate the range in normal cycling women.) 
subject X who did not menstruate at all and, in spite of mechanical contraceptive precau­
tions, turned out to be pregnant. 
The subjects I, II, III, VI and VIII demonstrated (late) proliferative aspects in their 
endometrial biopsies. Their hormonal data were constantly similar with relatively high 
levels of FSH and low levels of LH and almost no 17/?-oestradiol during the stage of hyper-
prolactinaemia. Before the onset of the first vaginal bleeding, always a more or less marked 
elevation in the periphereal levels of progesterone was noticed with a duration of less than 
9 days. In Fig. 3 the hormonal data of subject II are shown to illustrate the major relation­
ships. 
Subject IX was the only one who menstruated while in full lactation. Her hormonal 
data are shown in Fig. 4. In spite of normal levels of FSH and LH, virtually no response 
in the periphereal levels of 17^-oestradiol was seen; this was in agreement with the findings 
of her endometrial biopsy (Table 1). 
In all ten cases HPL was determined during late pregnancy and the first 3 days after 
delivery. Within 24 h post-partum the amount of measured HPL in all patients was below 
the limit of detection. 
DISCUSSION 
During late pregnancy and the early post-partum period high levels of prolactin above 
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FIG. 2. Subject X. The relationship between breast-feeding, peripheral plasma levels of pro­
lactin, FSH, LH, 17/f-ocstradiol and progesterone during the Puerperium. (Horizontal lines 
indicate the range in norrrul cycling women.) 
100 ng/ml were found; these findings are in agreement with earlier reports (Reyes et al., 
1972; Tyson et al., 1972; Tyson & Friesen, 1973; Brun del Re et al., 1973). After approxi­
mately 7 days a decrease is seen in all cases with marked fluctuations due to the varying 
time interval between suckling and venepuncture (Tyson et al., 1972). However, as long as 
lactation persisted, in nine cases out often, prolactin levels well above 30 ng/ml were found. 
This is the upper level of the normal range, and the tenth patient (patient IX) demonstrated 
levels in the upper normal range. During the period of weaning, a steady decrease in pro­
lactin concentrations occurred; as soon as breast-feeding had definitely been stopped, all 
levels were within the normal non-pregnant range below 30 ng/ml with fluctuations. The 
two patients with persistent lactation for more than 90 days did not show levels below 
approximately 60 ng/ml even though the interval between suckling and taking the blood 
samples ranged from 20 min to more than 4 h. This seems to disagree with an earlier report 
by Tyson et al. (1972) of normal prolactin concentrations in breast-feeding mothers 80 days 
post-partum. So prolactin does seem necessary both for the initiation and the prolongation 
of breast feeding; however, the amount necessary for the maintenance is less. 
In all ten cases FSH was scarcely detectable during late pregnancy and the early post­
partum period. At day 7 in two cases and between day 9 and 18 in the rest of the group, 
there was an increase in FSH concentration to normal cyclic levels. This is in disagreement 
with the findings of Crystle et al. (1970) and Hanson et al. (1970) who reported persisting 
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low levels of FSH during the first 30 days after delivery. However, the observations of Jafife 
et al. (1969) and Reyes et al. (1972) support our findings. 
After the increase of FSH to normal cyclic levels all patients demonstrated a further 
increase to levels found in the upper normal cyclic range or even above this range for approxi­
mately 30 days; thereafter there was a slow decrease to normal cyclic levels. Even in patients 
with persistent hyperprolactinaemia these relatively high FSH levels persisted. 
The high levels of 'LH' found in the early post-partum period must be due to cross 
reaction in the assay system with HCG, as reported by others (Faiman et al, 1968; Kell er, 
1968; Jane et al., 1969; Reyes et al, 1972). This clearance of HCG and its breakdown 
products was completed between day 7 and day 17 (Table 3) as at that moment values of 
approximately 30 mIU/ml were measured. The clearance of placental 17/}-oestradiol was 
completed much earlier and does not seem responsible for the sustained FSH depression. 
However, it is tempting to propose a relationship between the increase of FSH with the 
completed HCG clearance. 
After HCG clearance, low to very low values of LH were found despite high levels of 
FSH in all cases. In patients with persistent lactation LH remained low for an even longer 
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period of time. The return of LH to the normal cyclic range usually occurred with a little 
delay, but paralleled the slight increase of 17/?-oestradiol to levels found in the follicular 
phase. This may indicate a positive feedback of 17^-oestradiol on the hypothalamus to 
release luteinizing hormone-releasing hormone which is then responsible for the LH release 
(Ross & Vande Wiele, 1974). This is in agreement with the findings of Crystle et al. (1973) 
who observed this mechanism taking place after administration of exogenous ethinyl 
oestradiol at a low dose from day 10 to day 14. However, these authors thought that the 
same mechanism stimulated FSH release. This seems unlikely as FSH levels are restored 
spontaneously at exactly this time, as demonstrated in this study. Thus, in spite of relatively 
large amounts of FSH, the ovaries are insensitive to this stimulus so that there is no secre­
tion of 17/?-oestradioI which is necessary for the initiation of LH production. The duration 
of this stage seems closely related to the period of hyperprolactinaemia, and as already 
suggested by others (Reyes et al., 1972; Zarate et al., 1972; Crystle et al., 1973) it strongly 
indicates that the ovaries are the more refractory component of the hypothalamic-pituitary-
ovarian axis following delivery. This introduces an element of doubt with regard to the 
older hypothesis suggesting a reciprocal relationship between the secretion of gonadotro-
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phins (FSH and LH) on the one hand and prolactin on the other (Sulman, 1970). In fact, 
prolactin has recently been shown to demonstrate affinity to ovarian tissue (Friesen, 1973, 
personal communication; Turkington et al., 1973). 
In spite of the absence of signs of secretory activity in the endometrial biopsies in 
five cases, more or less elevated progesterone levels were found during the last days before 
vaginal bleeding. This suggests that the first vaginal bleeding occurring after weaning is 
preceded by at least some corpus luteum function, although this may be insufficient as 
compared to normal corpora lutea. The endometrial biopsies in these cases do not give 
accurate information concerning the hormonal status at that particular moment. 
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SUMMARY 
Serial plasma levels of prolactin follicle-stimulating hormone (FSH), luteinizing 
hormone (LH), 17/?-oestradiol (E) and progesterone (P) were determined by 
radioimmunoassay in ten healthy women during late pregnancy and the Puerperium 
during inhibition of lactation by Bromergocryptine. This medication was con­
tinued until the occurrence of the first menstruation, at which point an endo­
metrial biopsy was taken. Prolactin was very effectively suppressed by Bromergo­
cryptine in all patients, as was lactation. FSH was nearly undetectable during late 
pregnancy and the first week post-partum with an increase back to normal levels 
between day 7 and day 12. Thereafter FSH levels were within the normal cyclic 
range. Following clearance of human chorionic gonadotrophin (HCG) during the 
first 2 weeks post-partum, LH was found within the normal cyclic range in all 
patients. From day 7 E increased in nine often patients to reach levels during the 
fourth week which are seen normally at the moment of the pre-ovulatory E-surge 
in cycling women. In eight of the ten cases this was concomitant with high levels 
of LH. The tenth patient showed a high E level at day 36. Ρ was fully excreted within 
7 days and remained low until approximately day 20. Thereafter an increase was 
demonstrated with levels as found during the luteal stage of the menstrual cycle in 
nine patients within 33 days and within 40 days in all ten patients. The endometrial 
biopsies showed clear signs of secretory activity. The probable action of prolactin 
on ovarian function is discussed. It is suggested that during the Puerperium the 
ovaries are the more refractory part of the hypothalamic-pituitary-ovarian 
axis, due probably to an influence of prolactin on the ovarian steroid synthesis. 
Correspondence: Dr R. Rolland, The Milton S. Hcrshey Medical Center, Department of Endocrinology' 
The Pennsylvania Stale University, Hershey, Pennsylvania 17033, U.S.A. 
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Prolactin has been thought to influence the restoration of ovarian function in the early 
post-partum period through an antigonadotrophic activity at the level of the ovaries 
(Reyes et al., 1972; Zarate et ai, 1972). In a recent study (Rolland étal, 1975) it was shown 
that in spite of high levels of FSH at day 10 post-partum approximately, the ovaries are 
insensitive to this FSH stimulus as no 17/?-oestradiol is found. Plasma levels of LH were 
low as long as the prolactin levels were above 30 ng/ml. 
Bromergocryptine (2-Br-alpha-ergocryptine; CB 154, Sandoz, Basle, Switzerland) has 
been shown to have a specific anti-galactic activity. Hardly any side effects of this drug have 
been noted. This anti-galactic activity has been shown in several experimental animal 
studies (Fliickiger & Wagner, 1969; Billeter & Fliickiger, 1971), in puerperal women (Varga 
et al., 1972; Del Pozo et al., 1972; Rolland & Schellekcns, 1973), in women with galactor-
rhoea and menstrual disturbances (Lutterbeck et al., 1971 ; Besser et ai, 1972; Jaszmann & 
Sternthal, 1974; Rolland et al., 1974) and in men with galactorrhoea and impotence 
(Besser et al., 1972). The drug blocks the release of prolactin from the hormone-producing 
pituitary cell (Pasteéis et al., 1971 ; Del Pozo et al., 1973). 
We decided to administer this drug during the Puerperium in order to study whether 
inhibition of prolactin release would substantiate our hypothesis that the presence of pro-
lactin is responsible for the delayed restoration of cyclic ovarian function in post-partum 
lactating women. A quicker restoration of ovarian function might therefore be expected 
when this drug is given. 
SUBJECTS 
Ten healthy volunteers, who had given proof of adequate lactation for more than 2 weeks 
during a previous Puerperium, were studied. Their menstrual cycles prior to pregnancy 
were reported as normal with a duration of approximately 4 weeks. The pregnancies were 
all uneventful up to the study which was started at the 36th week. 
The women were admitted to hospital when signs of labour were obvious. From the 36th 
week of pregnancy venous blood samples were drawn weekly; then daily during the first 
7 days post-partum, then twice weekly until the occurrence of the first vaginal bleeding 
recognized by the subject as a normal menstruation. At this stage endometrial biopsies were 
taken to determine the stage of endometrial development. 
Within 24 h of delivery in all subjects except one (patient II) 2-5 mg Bromergocryptine 
was administered twice daily during breakfast and supper; this dose had proved sufficient 
to inhibit puerperal lactation in a previous study (Rolland & Schellekens, 1973). All subjects 
delivered their babies vaginally except one (patient II) who was delivered by Caesarean 
section; in this case, medication was started 48 h after delivery. All ten women continued 
to take Bromergocryptine until their first menstrual period. 
During the first 7 days post-partum nearly all blood samples were taken between 07.00 
and 08.00 hours, thereafter always between 09.00 and 12.00 hours. The blood was collected 
in heparinized tubes, immediately chilled on ice, centrifuged at 2500 rev/mi η for approxi­
mately 8 min and the plasma stored at -20CC until assay. In general all samples from one 
subject were measured in the same assay run. 
M E T H O D S 
Prolactin, HPL, FSH, LH, 17/f-oestradiol and progesterone were all measured by radio-
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TABLE 1. The duration of post-partum amenorrhoea and the stage of 
endometrial development in the Puerperium in ten women during 
inhibition of lactation with Bromergocryptme. 
Patient 
I 
II 
III 
IV 
V 
VI 
VII 
VIII 
IX 
X 
Mean 
Range 
Duration of post-partum 
amenorrhoea (days) 
32 
48 
28 
33 
36 
33 
34 
27 
43 
37 
35 
27-48 
Endometrium 
development 
Late proliferative 
No diagnosis 
Late proliferative 
Late proliferative 
Early secretory 
Mixed proliferative-secretory 
Late secretory 
Mixed proliferative-secretory 
Pseudo decidual 
Late secretory 
TABLE 2. Plasma prolactin levels during late pregnancy and the 
early post-partum period in nine women with puerperal inhibi-
tion of lactation by Bromergocryptine 
Plasma prolactin (ng/ml) 
Weeks of pregnancy No. of 
cases Mean SD Range 
35-36 6 312-8 814 203-414 
37-38 9 316 4 61-5 244-447 
39-40 8 338 5 147-1 178-641 
41-42 5 432-6 173-4 221-670 
Days from delivery 
1 
2 
3 
4 
5 
6 
7 
9-12 
13-15 
16-19 
20-22 
23-26 
27-29 
30-33 
34-36 
37-40 
42 
9 
9 
9 
9 
9 
9 
9 
9 
9 
9 
9 
9 
9 
9 
7 
3 
1 
42-1 
25-3 
19-9 
17 0 
17-4 
26 8 
27-8 
130 
11-7 
18-3 
10-3 
110 
6-9 
17-4 
19 8 
6-3 
7 0 
181 
14-4 
15-7 
120 
150 
21-8 
21-8 
5-7 
5-6 
34-4 
6-5 
7-2 
3-5 
24-3 
24-3 
2-4 
— 
21-66 
9-56 
8-49 
8-42 
6-53 
5-54 
5-65 
6-22 
5-24 
3-110 
3-23 
3-23 
3-13 
3-77 
3-71 
6-8 
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immunoassay. The methods used and the normal values are described in the first part of 
this study (Rolland et al, 1975). 
RESULTS 
The duration of post-partum amenorrhoea and the stage of endometrial development at 
the moment of the first vaginal bleeding after delivery, are shown in Table 1. The mean 
duration of amenorrhoea was 35 days with a range of 27-48 days. Clear signs of secretory 
TABLE 3 Plasma FSH levels during late pregnancy and plasma FSH and LH (HCG) levels (mIU/ml 
plasma 2nd IRP of human menopausal gonadotrophm(HMG)) during the early post-partum period in 
nine women with puerperal inhibition of lactation by Bromergocryptine 
Plasma FSH Plasma LH (HCG) 
Weeks of No of 
pregnancy cases Mean SD Range Mean SD Range 
35-36 6 <1 <1 — 
37-38 9 < l <1 — 
39-40 8 <1 <1 — 
41-42 5 10 14 < l - 3 
Days from delivery 
1 
2 
3 
4 
5 
6 
7 
9-12 
13-15 
16-19 
20-22 
23 26 
27-29 
30-33 
34-36 
37-40 
42 
9 
9 
9 
9 
9 
9 
9 
9 
9 
9 
9 
9 
9 
9 
7 
3 
1 
< i 
< 1 
< l 
< 1 
< i 
1 7 
2 8 
8 0 
8 2 
7 7 
6 2 
8 0 
6 9 
5 4 
5 3 
3 8 
3 
< 1 
< 1 
< 1 
< 1 
< 1 
2-8 
3 7 
3·5 
3 0 
19 
2 5 
3 9 
5 0 
1 9 
3 3 
4 0 
— 
— 
— 
— 
—. 
— 
< l - 7 
< l - 8 
2-12 
4-14 
4-10 
4-11 
3-15 
<1 -19 
2-8 
< l - 9 
< l - 8 
— 
>200 
>200 
>200 
>200 
>200 
>200 
193 
76 4 
412 
36 8 
34 7 
65-2 
36 9 
37 3 
23 6 
218 
— 
— 
— 
— 
— 
— 
— 
156 
61-3 
313 
164 
167 
76-2 
26 9 
39·1 
136 
3 5 
— 
— 
— 
— 
— 
— 
— 
4 2 ^ 1 9 
21-204 
18-120 
19-71 
14-65 
11-253 
10-98 
9-137 
8-52 
18-25 
— 
activity were observed in six and late proliferative changes in three of the endometrial 
biopsies. Unfortunately no histological examination could be performed in subject II. 
The difference in duration of post-partum amenorrhoea in these ten women compared to 
ten nursing women as earlier reported (Rolland et al, 1975), is statistically significant 
{P<0001, Student's Mest). 
The hormonal observations in the nine cases delivered vaginally are taken together as 
they all show similar patterns. Their data during the observation time are shown in Tables 
2-4 and Fig. 1. 
Prolactin concentrations (Table 2, Fig. 1) were very effectively suppressed by Bromergo-
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cryptine after delivery At the end of the study period an increase was sometimes noticed 
in the range of prolactin concurrently with a slight increase of the mean. 
FStf (Table 3, Fig 1) was barely detectable during late pregnancy and the early post­
partum period At day 6 a slight increase was noted and all women demonstrated FSH 
levels within the normal cyclic range at day 12 Until day 23 the mean FSH values wert 
within the normal cyclic range; only a few levels were found above the upper normal limit. 
Between day 23 and 29 marked variations were observed with values clearly above the 
upper normal level of the proliferative or luteal stage of the cycle. Thereafter a decrease to 
levels as found during the normal cycle was observed. In fact, some of these FSH values 
found between day 23 and day 29 reached a level seen during the pre-ovulatory FSH peak 
in normal cyclic women. 
TABLF 4 Plasma 17/i-oestradioI (pg/ml plasma) and progesterone (#g/dl plasma) levels in 
eight women during late pregnancy and in nine women during the early post-partum period 
during inhibition of lactation by Bromergocryptme 
Weeks of 
pregnancy 
35-38 
39-41 
Days from delivery 
3 
7 
9-12 
13-15 
16-19 
20-22 
23-26 
27-29 
30-33 
34-36 
37-40 
42 
No of 
cases 
8 
8 
9 
9 
8 
9 
9 
9 
9 
9 
9 
7 
4 
1 
Plasma 170-oestradiol 
Mean 
26255 
28383 
153 
63 
80 
114 
192 
261 
229 
282 
161 
164 
127 
178 
SD 
10283 
9948 
75 
43 
18 
42 
133 
193 
107 
178 
91 
78 
50 
— 
Range 
9000-37800 
12000-41200 
63-276 
18-140 
60-112 
53-180 
74-495 
69-66L 
136-438 
163-633 
80-358 
81-288 
64-180 
— 
Plasma progesterone 
Mean 
17 20 
19 50 
040 
0 05 
004 
0 02 
0 03 
0 10 
0 34 
0 77 
104 
0 70 
0 62 
044 
SD 
540 
590 
0 20 
— 
— 
— 
— 
0 22 
0 54 
0 71 
100 
0 50 
0 32 
— 
Range 
9 90-25 20 
14 00-3140 
016-0 75 
0 02-0 10 
0 02-0 06 
0 01-003 
0 01-0 06 
0 01-0 67 
0 01-171 
0 02-1 94 
0 12-2 23 
0 02-1 34 
019-0 98 
— 
LH (Table 3, Fig. 1). During the early puerpenum, HCG was measured together with LH 
as these hormones cross react in our assay system. The interfering HCG and its metabolites 
were found until day 16 in some cases. Between day 16 and 23 the measured hormone 
concentrations were nearly within the normal cyclic range of LH with a mean value precisely 
within the levels found during the follicular phase of the menstrual cycle. Between day 23 
and day 33 marked variations were found with an increase of the mean and also of the range 
of measured LH In four patients LH levels as normally seen at the moment of the pre­
ovulatory LH peak were found during this period. After day 33 the mean LH value decreased 
and during the rest of the observation time remained at the level seen during the luteal phase 
of the menstrual cycle These findings correlate well with those of FSH, showing an increase 
of the mean and the range between day 23 and 29. 
\Ίβ-0estradiol (Table 4, Fig 1) which stayed high during late pregnancy, was nearly fully 
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FIG. 1. The mean and SD of prolactin, FSH and LH, 17/?-oestradiol and progesterone during 
late pregnancy and the Puerperium during Bromergocryptine medication in nine healthy 
women. (Horizontal lines indicate normal range in cycling women.) 
cleared from the circulation within 7 days of delivery. At day 7 a mean level as in the early 
proliferative stage of the cycle was found. Thereafter a steady increase was observed in all 
nine cases to concentrations equal to that found during the preovulatory 17/?-oestradiol 
surge in normal cyclic women. In all nine cases these high levels were followed by an increase 
in the concentration of progesterone to above 0-12 ¿ig/dl plasma indicating luteinization 
of the follicle. Subsequently the amount of 17/i-ocslradiol decreased in the group as a whole 
and remained at the level normally seen during the luteal phase of healthy cyclic women. 
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Progesterone (Table 4, Fig. I). Within 7 days post partum, the high plasma progesterone 
levels observed at tei in decreased to nearly undetectable levels. After day 20 an increase in 
the mean of the progesterone levels was noted indicating that, in some cases, active corpora 
lutea had been formed Eight patients showed progesterone levels above 0-50 ^ g/dl after day 
20, the ninth showed a maximum progesterone level of 0-33 /¿g/dl indicating that some 
luteinization at least had taken place. 
As the blood samples were only taken twice weekly, an ovulatory LH surge could only be 
found accidentally. In eight of the nine cases, however, a definite elevation of the LH level 
was found at a particular moment indicating that the blood sample had been taken at the 
start, middle or end of the ovulatory LH surge (Table 5) These 'peaks' were found on the 
same day as the 17/?-oestradiol peak in seven cases and 2 days later in one case and were all 
followed by an increase in the amount of progesterone above 0-50 ^g/dl plasma. The time 
interval between the restoration of normal FSH activity (above 2 mIU/ml) and the LH 'peak' 
TABLE 5 The time course between the moment of restored FSH levels 
(above 2 mIU/ml plasma 2nd IRP of HMG) and the first noticed 
17/f-oestradiol and LH 'peak' followed by an increase in plasma 
progesterone levels above 0 12 /yg/dl plasma in the early post-partum 
period in eight women with inhibition of lactation by Bromergocryptme 
А В С Difference 
Patient FSH within normal 17/f-oestradiol LH'peak' А—С 
range at or peak at day: at day: (days) 
between day(s): 
III 
IV 
V 
VI 
VII 
VIII 
IX 
X 
5 
7-12 
9 
7-9 
7 
7-11 
10 
6 
19 
29 
27 
20 
23 
23 
31 
24 
19 
29 
27 
20 
23 
25 
31 
24 
14 
17-22 
18 
11-13 
16 
14-18 
21 
18 
gives the approximate duration of the proliferative stage of the first menstrual cycle post­
partum. In these eight cases it ranged from 11 to 22 days which is nearly within the range of 
normal cycling women. 
The hormonal data of subject II are shown in Fig. 2. She was delivered by Caesarean 
section because of a contracted pelvis Bromergocryptme was given at approximately 48 h 
after delivery. Unfortunately she also received during this early post-partum time drugs 
known to stimulate prolactin release (Promethazinum and Chlorpromethazinum). It is 
only at such a late stage as between day 12 and day 15 that prolactin falls below the upper 
normal level of 30 ng/ml plasma as found in non-pregnant women. Persistently low levels 
were found thereafter. 
Finally the hormonal data of subject X arc shown alone in Fig 3 to serve as a model for 
restoration of ovarian function in the post-partum period in absence of high prolactin 
levels with an ovulatory LH peak at day 24 post-partum and an endometrial biopsy taken 
at day 37 showing clear post-ovulatory signs. 
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FIG. 2. Subject Π. The relationship between prolactin, FSH and LH, 17/?-oestradiol and 
progesterone during late pregnancy and the Puerperium during Bromergocryptine medication. 
(Horizontal lines indicate normal range in cycling women.) 
In all ten cases HPL was determined during late pregnancy and the first 3 days after 
delivery. Within 24 h post-partum the amount of measured HPL fell below the limit of 
detection. 
D I S C U S S I O N 
In this study the strong inhibitory action of Bromergocryptine on prolactin secretion in the 
early post-partum period has been demonstrated again with complete inhibition of lacta­
tion. There were no complaints of engorged or painful breasts during the study. 
As in lactating women, FSH is practically indétectable during late pregnancy and the 
first week post-partum. Thereafter there is a return to normal cyclic levels. The timing of this 
increase in FSH seems to occur more discretely in the Bromergocryptine treated women, 
i.e. between days 7 and 10 post-partum, than in the lactating women. In the latter group 
the time range of the FSH surge to (supra)normal levels occurs between days 7 and 18. 
There was no clear correlation, however, between the time at which moment the FSH surge 
took place and the plasma prolactin levels at that particular moment (Rolland et al., 1975). 
The low plasma levels of FSH during pregnancy have been thought to be due to the large 
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FIG. 3. Subject X. The relationship between prolactin, FSH and LH, 17/?-oestradiol and 
progesterone during late pregnancy and the Puerperium during Bromergocryptine medication. 
(Horizontal lines indicate normal range in cycling women.) 
amount of oestrogens produced by the placenta (Jaffe et al., 1969). The present study 
suggests, however, that FSH remains persistently low for at least 7 days post-partum in both 
the lactating and the Bromergocryptine treated women although 17/?-oestradiol has nearly 
disappeared by the third day post-partum. The timing of the restoration of FSH activity, 
however, correlates much better with the time necessary for HCG and its metabolites to be 
fully cleared. It appears that in early pregnancy the opposite mechanism occurs in that FSH 
levels become undetectable as HCG levels increase (Jane et al., 1969; Rolland et al., 1974, 
1975). 
It is interesting to note that in the Bromergocryptine treated group the FSH levels return 
to levels as found in the normal cyclic range. This is in contrast to the post-partum FSH 
levels in lactating women which show clearly supra-normal FSH levels during the same 
period (Rolland et al., 1975). 
As reported by others, HCG and its metabolites are slowly cleared post-partum. This 
process takes approximately a fortnight (Faiman et al., 1968; Jaffe et al., 1969; Reyes et al., 
1972; Rolland étal., 1975). The administration of Bromergocryptine appears not to influence 
this process. Thus in both groups LH may be detected only 12 days post-partum. A clear 
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discrepancy, however, is observed with respect to the LH levels in the lactating and Bromer-
gocryptine treated women. In the former group LH remains scarcely detectable during the 
stage of hyperprolactinaemia (above 30 ng/ml), while in the latter group LH (as well as 
FSH) are within the range of normal cyclic women from about day 15 (day 10) post-partum 
onwards. 
It is of particular interest that in the Bromergocryptine treated group at about day 12 
post-partum, the plasma levels of 17^-oestradiol are within the limits found in the normal 
early pre-ovulatory phase of the menstrual cycle (Fig. 1). 
This is in sharp contrast to the plasma l7/?-oestradiol levels in lactating women which 
remain barely detectable for a long time. Thus it seems that the presence or absence or 
prolactin plays a major role in the restoration of normal cyclic LH levels and/or normal 
cyclic 17/?-oestradiol levels. It is at present particularly difficult to decide at what level 
prolactin is exerting its inhibitory role, i.e. at the level of the ovaries or at the level of the 
pituitary or at both levels. The results of subject II (Fig. 2) suggest that the inhibitory effect 
of prolactin is at the level of the ovaries. This woman had prolactin levels above 30 ng/ml 
in 12-15 days, although under medication. Her LH levels decreased to normal cyclic values 
and remained in this range. During this period the plasma ]7/?-oestradiol levels remained 
low, at less than 50 pg/ml. It seems that only after prolactin has fallen to below approxi-
mately 30 ng/ml do the ovaries become capable of producing 17/?-oestradiol in the presence 
of normal FSH levels. The mean values of those parameters measured in the nine other 
women in the Bromergocryptine treated group (Fig. 1) and the values of lactating women as 
earlier reported (Rolland et al., 1975), support this view. 
In the group of women under medication, ovulatory levels of FSH and LH were found 
4 weeks post-partum (Table 3 and Fig. 1). Concomitant with these events, the plasma 
progesterone levels rose to levels found in the normal luteal phase of the menstrual cycle. 
This indicates that active corpora lutea had been formed. In the group of lactating women 
only one out of the ten patients studied during the same period of 40 days had progesterone 
levels above 0-12 /zg/dl plasma indicative of luteinization of the follicle (Rolland et al., 
1975). 
From the present study and the previous one (Rolland et al., 1975) the following con-
clusions seem justifiable: (a) During the period of breast-feeding prolactin remains necessary. 
During sustained lactation, however, the amount of prolactin is much less than during the 
period of initiation, (b) During late pregnancy and the early post-partum period the FSH 
levels are nearly undetectable. They become detectable and remain in the (supra)normal 
range 7-14 days after delivery. This seems related more to the duration of clearance of HCG 
and its metabolites which take place during the first 2 weeks post-partum than to theduration 
of clearance of placental oestrogens which is almost complete within 72 h after delivery. 
(c) High levels of prolactin during the period of lactation are clearly correlated to relatively 
high levels of FSH and low levels of LH and 17/?-oestradiol. When prolactin release from 
the pituitary gland is inhibited by Bromergocryptine, normal ovulatory function is immedi-
ately restored as soon as the amount of FSH reached normal cyclic levels above 2 mIU/ml 
plasma (2nd IRP). The increase in 17/?-oestradiol seems to precede and to initiate the release 
of LH. This is in agreement with the findings of Crystle et al. (1973) who observed this 
mechanism taking place after administering ethinyloestradiol at a low dose from days 10 to 
14 post-partum. Thus, it is tempting to assume an inhibiting influence of prolactin on 
ovarian steroid synthesis in humans post-partum. 
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SUMMARY AND CONCLUSIONS 
Article I: 
In this paper the effect of Bromergocryptine on puerperal lactation was studied. 
It was shown that inhibition of lactation could be achieved succesfully using this drug and 
also that already established lactation could be suppressed. However, the duration of 
treatment had to be approximately 21 days to prevent initiation or recurrence of lactation 
after stopping the drug administration. As this drug acts by blocking the release of 
prolactin from the pituitary gland, the essential role of prolactin on puerperal lactation has 
been demonstrated indirectly. 
Conclusion: 
Bromergocryptine is an effective drug for inhibition of puerperal lactation and also for 
suppression of already established lactation. 
Article 11: 
In the second paper three patients with galactorrhea due to hyperprolactinaemia and 
menstrual disturbances were studied. 
Inhibition of prolactin release from the pituitary gland by Bromergocryptine, resulted in 
the disappearance of the galactorrhea with concomitant restoration of ovarian function. 
Laboratory findings before treatment showed elevated plasma prolactin levels, FSH and LH 
levels within the normal range and low to very low levels of total oestrogens in 24 hrs. urine. 
During treatment, prolactin concentrations decreased to values within the normal range 
while total urinary oestrogen excretion increased. Thereafter menstrual periods appeared in 
all three patients. Hormonal studies, as well as histological examination of endometrium 
biopsies, were indicative that ovulations did take place, which was proved by a pregnancy in 
one of them. 
Conclusions: 
A: In patients with hyperprolactinaemia, ovarian function is influenced directly or 
indirectly by prolactin. 
B: Bromergocryptine is also an effective drug for the treatment of non-puerperal 
galactorrhea. While it gives a suppression of the milkproduction, it also restores the ovarian 
functions. 
Article no. Ш, part 1: 
This part of the third paper examined the hormonal changes during the Puerperium in 
normal lactating women. 
During the period of lactation elevated peripheral plasma levels of prolactin were found in 
all cases. The stage of hyperprolactinaemia was characterized by relatively high plasma 
levels of FSH, low levels of LH and very low concentrations of oestradiol-17 β . This may be 
indicative of poor follicular development. 
After weaning, normal levels of prolactin were found with concomitant increase in the 
concentrations of oestradiol-17/} and also of LH. However, there seemed to be a short 
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delay between the increase of oestradiol-17 β and that of LH. 
Thereafter, normal cyclic levels were found of all hormones measured. The first vaginal 
bleeding after delivery was mostly preceeded by a short luteal stage. 
Conclusions: 
A: Prolactin is necessary for both the initiation and the maintenance of puerperal lactation. 
Once the lactation is well established, however, the prolactin concentrations in blood 
decrease to lower values than during the period of initiation. 
B: The delayed restoration of normal oestradiol-17 β concentrations in plasma in lactating 
women is correlated to the time of hyperprolactinaemia. 
Article no. Ш, part 2: 
This part of the third paper examined the hormonal changes during the Puerperium in non-
lactating, Bromergocryptine treated women. The drug administration started immediately 
after delivery and was continued until after the occurence of the first vaginal bleeding. 
Plasma prolactin concentrations were within the normal nonpregnant range within two days 
after delivery and remained so throughout the study. After restoration of normal plasma 
levels of FSH during the second week postpartum, normal concentrations of LH were found 
as soon as the clearance of HCG had taken place. Concomitant with the restoration of 
normal gonadotrophic activity, an increase in the amount of oestradiol-17 /3 in plasma was 
found from the seventh day after delivery until high preovulatory levels were reached during 
the third to fourth week. At this time an increase in plasma progesterone was found and 
within 40 days postpartum all women showed plasma levels of this hormone indicating the 
presence of corpora lutea. Thus in absence of elevated prolactin levels, the ovaries are 
sensitive to normal gonadotrophic stimulation occuring during the second week postpartum 
resulting in restoration of normal ovarian functions. 
Conclusions: 
A: During late pregnancy and the first one to two weeks of the Puerperium, plasma FSH is 
hardly detectable. This decrease is not correlated to the amount of prolactin present in 
plasma. 
B: Inhibition of pituitary prolactin release after delivery allows the ovaries to react 
immediately with production of oestradiol-17 β as soon as normal gonadotrophic activity is 
restored. 
C: Women using Bromergocryptine for inhibition of puerperal lactation should be 
instruated to take contraceptive precautions during the Puerperium because the first 
ovulation is likely to be anticipated through the medication. 
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SAMENVATTING EN CONCLUSIES 
Artikel I: 
In deze studie wordt het effect van Bromergocryptine op puerperale lactatie bestudeerd. 
Met dit medicament bleek het mogelijk de lactatie volledig te onderdrukken. Ook wanneer 
de lactatie reeds op gang was gekomen, werd het met succes toegepast. De behandeling 
moet echter gedurende 3 weken worden voortgezet om een recidief te voorkomen. 
Aangezien deze stof de afgifte van prolactine uit de hypophyse blokkeert, wordt tevens 
langs indirecte weg aangetoond dat prolactine een essentiële rol speelt in het mechanisme 
van de puerperale lactatie. 
Conclusie: 
Bromergocryptine is een werkzaam medicament wanneer de puerperale lactatie voorkomen 
moet worden en wanneer een reeds tot stand gekomen lactatie moet worden geremd. 
Artikel Π: 
In de tweede studie worden drie patiënten met een pathologische galactorrhoe en 
menstruatiestoornissen uitvoerig bestudeerd. 
Via remming van de prolactine-afgifte uit de hypophyse met behulp van Bromergocryptine 
werd de pathologische galactorrhoe genezen, terwijl de ovariumfunctie zich tevens bleek te 
herstellen. Laboratoriumbepalingen vóór het begin van de behandeling toonden aan: een 
verhoogde spiegel van prolactine, FSH- en LH-waarden binnen de normale grenzen, en lage 
tot zeer lage spiegels van oestrogène stoffen in de 24-uurs urine. Tijdens de behandeling 
daalden de prolactine-spiegels tot de norm, terwijl de uitscheiding van de oestrogène stoffen 
in de urine steeg. Kort hierna ontstonden bij alle patiënten menstruele bloedingen. Op 
grond van hormoonbepalingen en op grond van het histologisch onderzoek van het 
endometrium kan men aannemen dat de cycli ovulatoir werden. Bij een van de patiënten 
werd het bewijs hiervan geleverd toen zij tijdens de behandeling zwanger werd. 
Conclusie: 
A: Bij patiënten met verhoogde spiegels van prolactine wordt de ovariumfunctie direct of 
indirect beïnvloed door het prolactine. 
B: Bromergocryptine is tevens een werkzaam geneesmiddel bij de behandeling van niet-
puerperale galactorrhoe. Het verhindert niet alleen de melkproductie, doch het leidt ook tot 
een herstel van de ovariumfuncties. 
Artikel Ш, deel 1: 
In deze studie worden de hormonale veranderingen beschreven, welke werden waarge­
nomen bij gezonde lacterende kraamvrouwen. 
Bij alle vrouwen werd een verhoogde spiegel van plasma-prolactine gevonden. In deze fase 
werd tevens een betrekkelijk hoge spiegel gevonden van FSH, met lage waarden van LH en 
zeer lage waarden van oestradiol-17/3 . Dit wijst op een slechte ontwikkeling van het 
folliculaire apparaat. 
Na het staken van de borstvoeding bleken de prolactine-spiegels tot de norm te zijn 
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gedaald, gepaard gaande met een stijging van de concentraties van oestradiol-17/5 en LH. 
Het oestradiol-17 β leek eerder te stijgen dan de LH-spiegels. In aansluiting hieraan werden 
van alle hormonen waarden gevonden, zoals deze voorkomen in normale cycli. De eerste 
vaginale bloeding na de bevalling werd meestal voorafgegaan door een korte luteale fase. 
Conclusie: 
A: Prolactine is noodzakelijk zowel voor het op gang brengen, als voor het onderhouden van 
de puerperale lactatie. Zodra de lactatie echter goed op gang is gekomen, dalen de 
prolactine-spiegels tot lagere waarden, dan die, welke gevonden worden in de beginperiode 
van de lactatie. 
B: Het vertraagde herstel van de normale oestradiol-17 β -spiegels in het plasma van de 
lacterende vrouwen is gekoppeld aan de duur van de verhoogde prolactine-spiegels. 
Artikel Ш, deel 2: 
Het tweede deel van het derde artikel beschrijft de hormonale veranderingen bij kraam­
vrouwen, die niet voedden, en die met Bromergocryptine werden behandeld. Deze 
behandeling begon kort na de bevalling en werd voortgezet tot na het verschijnen van de 
eerste vaginale bloeding. 
De plasma-spiegels van prolactine daalden binnen twee dagen na de bevalling tot waarden 
zoals deze voor niet zwangere vrouwen gelden, en bleven gedurende de gehele studie op dit 
lage niveau. Nadat de spiegels van FSH in het plasma in de tweede week na de bevalling tot 
de norm waren gestegen, werden bovendien normale waarden voor LH gevonden zodra de 
uitscheiding van HCG had plaats gevonden. Tijdens het herstel van deze normale 
gonadotrope stimulans werd een toename gevonden van oestradiol-17 β in het plasma, 
beginnend op de 7e dag post partum totdat in de 3e of 4e week post partum hoge pre-
ovulatoire waarden werden gemeten. Op dit moment werd tevens een toename van de 
hoeveelheid van plasma-progesteron gevonden, en binnen 40 dagen na de bevalling toonden 
alle vrouwen progesteron-spiegels welke wezen op een actief corpus luteum. Bij normale 
prolactine-spiegels blijken de ovaría dus reeds in de tweede week post partum gevoelig te 
zijn voor de normale gonadotrope prikkel, hetgeen resulteert in een herstel van de normale 
ovariumfuncties. 
Conclusie: 
A: Aan het einde van de zwangerschap en in de eerste veertien dagen van het kraambed kan 
bijna geen FSH worden aangetoond in het plasma. Deze daling van FSH is niet gecorreleerd 
aan de hoogte van de prolactine-spiegels. 
B: Een remming van de verhoogde prolactine-productie na de geboorte stelt de ovaría in 
staat terstond te reageren op de normale gonadotrope stimulans, hetgeen blijkt uit een 
productie van oestradiol-17 β . 
С: Vrouwen die Bromergocryptine gebruiken ter onderdrukking van de puerperale lactatie 
moeten erop worden gewezen, dat zij terstond anti-conceptieve maatregelen moeten nemen, 
omdat de eerste ovulatie door deze behandeling wordt vervroegd. 
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SAMMENDRAG OG KONKLUSJONER 
Artikkel I: 
Denne publikasjon omhandier en undersökelse av Bromergocryptinets innvirkning pâ den 
puerperale laktasjon. 
Det ble demonstrert at Bromergocryptin bade kunne hindre puerperal laktasjon og hemme 
allerede oppstâtt laktasjon. For â motvirke at det pâ nytt skulle oppsta laktasjon etter 
seponering av medikamentet var det nödvendig â behandle de forste 21 dager av puerperiet. 
Bromergocryptin blokkerer frigjöring av prolaktin fra hypofysen - og dette hormons viktige 
funksjon nâr det gjelder puerperal laktasjon har en herved indirekte demonstrert. 
Konklusjon: 
Bromergocryptin er et medikament som effektivt hindrer laktasjon og hemmer allerede 
oppstâtt laktasjon. 
Artikfcel II: 
Denne publikasjon omtaler tre pasienter som hadde galaktorrhoe forârsaket av 
hyperprolaktinemi og menstruasjonsforstyrrelser. 
Ved â motvirke frigjöring av prolaktin fra hypofysen med Bromergocryptin ble 
produksjonen av brystmelk hemmet samtidig som den ovarielle funksjon normaliserte seg. 
Laboratorieundersökelser foretatt för behandlingen viste for hëy konsentrasjon av 
prolaktin i plasma, normal plasmakonsentrasjon av FSH og LH og svaert lav totalmengde 
av östrogener i dögnurin. Etter pâbegynt behandling fait prolaktinkonsentrasjonen i 
plasma til normalt nivâ samtidig som det kom til ökning av den totale mengde östrogener i 
urinen. Noe senere menstruelle alle tre pasientene. Bade hormonelle undersòkelser og 
histologiske undersökelser av biopsier fra endometrium viste tydelige postovulatoriske tegn. 
Indikasjon pâ at ovulasjon hadde funnetsted var at en av kvinnene ble gravid. 
Konklusion: 
Α. Den ovarielle funksjon hos pasienter med hyperprolaktinemi er direkte eller indirekte 
pâvirket av prolaktin. 
B. Bromergocryptin er ogsä et effektivt medikament for behandling av galaktorrhoe. 
Samtidig som medikamentet hemmer laktasjonen, gjennopprettes den normale ovarielle 
funksjonen. 
Artikkel ΙΠ, del 2: 
Den forste del av denne artikkelen omhandler undersökelse av den hormonelle tilstand i 
puerperiet hos normale kvinner som ga brystmelk. Sa lenge brystmelk ble gitt forble 
plasmakonsentrasjonen av prolaktin forhöyet. FSH - mengden i plasma ble samtidig funnet 
noe öket, LH-konsentrasjonen noe minsket mens östradiol-17/i -konsentrasjonen ble funnet 
svaert lav. En slik hormonell tilstand indikerer liten eller ingen modning av de ovarielle 
follikler. Etter at brystmelkemaeringen var stoppet ble det pávist normale verdier av 
prolaktin i plasma samtidig med en rikning av bade ëstradiol-17 /3 og LH-konsentrasjonen. 
Stigningen av östradiol-17/J konsentrasjonen syntes â begynne för LH okningen. Alle 
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hormonelle konsentrasjoner var etter dette innenfor normalt omrâde for en ovulatorisk 
syklus. Den forste postpartale blödning hos disse kvinnene etterfulgte oftest en kort luteal 
fase. 
Konklusjon: 
A. Prolaktin er nödvendig for à igangsette og opprettholde puerperal laktasjon. Nàr 
melkeproduksjonen har kommet godt i gang er plasmakonsentrasjonen av dette hormonet 
lavere enn like etter födselen. 
B. Den langsomme gjenopprettelse av normal blodkonsentrasjon av östradiol-17 β 
tilsvarer den tiden en finner forökte mengder av prolaktin i sirkulasjonen. 
Artikkelin, del2: 
De hormonelle forandringer i puerperiet er undersökt hos kvinner som ikke önsket á gi 
brystmelk og som ble behandlet med Bromergocryptin. Medikamentet ble gitt fra like etter 
födselen til den forste blrtdning oppstod. Allerede to dager etter födselen ble 
konsentrasjonen av prolaktin i plasma funnet innenfor normalverien for ikke-lakterende 
kvinner. Verdiene holdt seg innenfor dette omràdet sa lenge undersökelsen varte. Normale 
verdier for FSH ble funnet etter en til to uker. Normale verdier for LH sa snart HCG var 
fullstendig utskilt. Samtidig som normale verdier ble màlt av de gonadotrope hormoner, 
ßkte plasmakonsentrasjonen av östradiol-17 β fra den syvende dag til den tredje uke i 
mengder som tilsvarte en preovulatorisk fase. Etter den tredje uke ökte plasma-
konsentrasjonen av progesteron og alie kvinnene hadde innen 40 dager etter partus 
plasmaverdier forenlig med aktiv corpus luteum-funksjon. Ovarene er sàledes fölsomme for 
stimulering av gonadotrope hormoner sä snart disse har normalisert seg - dvs.en til to uker 
etter födselen - dersom plasmakonsentrasjonen av prolaktin er normal. 
Konklusjon: 
A. Sent i graviditeten og i de to forste ukene etter födselen er FSH i plasma nesten ikke 
màlbar. Denne reduksjonen samvarer ikke med prolaktinkonsentrasjonen i plasma. 
B. Hemning av prolaktinfrigjöring fra hypofysen etter födselen gjor ovarene fölsomme for 
stimulering av de gonadotrope hormoner sa snart disse har normalisert seg. 
C. Kvinner som bruker Bromergocryptin for á hemme puerperal laktasjon bör tilrádes bruk 
av antikonsepsjonsmidler ved seksuelt samliv i denne tiden - da den forste ovulasjonen 
sannsynlig vil bli framskyndet pá grunn av medikamentet. 
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STELLINGEN 
1. Prolactine beïnvloedt de functie van het menselijk ovarium. 
(Dit proefschrift, Artikel 2 en 3) 
2. Bij het joderen van prolactine met J125 voor gebruik in radioreceptor studies, verdient 
de lactoperoxidase methode de voorkeur boven die waarbij gebruik wordt gemaakt van 
Chloramine-T. 
(Thorell, J.I. en Johansson, B.G. (1971) Biochim. Biophys. Acta, 251, 363. 
Franz, W.L. enTurkington, R.W. (1972) Endocrinology, 91, 1545. 
Shiu, R.P.C, en Friesen, H.G. (1974) Biochem. J., 140, 301.) 
3. De suggesties van Del Pozo et al. waarbij gesteld wordt, dat de oorzaak van de 
amenorrhoe bij patiënten met galactorrhoe-amenorrhoe syndroom zonder tumor van de 
hypophyse boven het niveau van de hypophyse gelegen is, wordt niet ten volle gesteund 
door de door hen vermelde gegevens. 
(Del Pozo, E., Varga, L., Wyss, H., Tous, G., Friesen, H., Wenner, R., Vetter, L. en 
VetwUler, A. (1974) J. Clin. Endocr. Metab. 39,18) 
4. Voor kunstverlossing van een kind in achterhoofdsligging, waarbij het voorliggend deel 
de bekkenbodem heeft bereikt en waarbij de kleine fontanel niet naar achteren wijst, is 
forcipale extractie een veilige methode voor zowel moeder als kind. 
(Niswander, K.R. en Gordon, M. (1973) Am. J. Obstet. Gynecol., 117,619.) 
5. Voor bewaking van het risico-kind in utero tijdens de zwangerschap, is het Cardioto-
cogram van groot belang, omdat waardevolle informatie zonder tijdsverlies, moeiteloos 
en zonder risico voor moeder en kind verkregen kan worden. 
(Beard, R.W., FUshie, G.M., Knight, C A . en Roberts, G.M. (1971) J. Obstet. 
Gynaecol. Brit. Comnwlth. 78, 865. 
Tushuizen, P.B.Th., Stoot, J.E.G.M, en Ubachs, 
J.M.H. (1974) Am. J. Obstet. Gynecol. 119, 638.) 
6. Exconisatie vormt zelden een onmisbare schakel bij de hedendaagse diagnostiek van het 
carcinoma colli uteri, stadium 0. 
(Schellekens, L.A. Abstracts XI International Cancer Congress, Florence, Italy, 
October 1974.) 
7. Aan ieder ziekenhuis met een verloskundige afdeling behoort tevens verbonden te zijn 
een kinderarts met speciale belangstelling voor perinatologie. 
8. Bij eventuele hernieuwde onderhandelingen omtrent toetreding tot de E.E.G., is de 
positie van Noorwegen versterkt doordat naast natuurprodukten als vis en hout, ook olie 
en gas aangeboden kunnen worden. 
Rune Rolland Nijmegen, 13 December 1974. 



